Visible node/edge number:
Node colors:
Node labels:

show label of nodes with degree >=

Node sizes:
Edge colors:
Edge widths factor:
Layout:

gravity >=

edgeLength =

GRN in network:

Notice: IE browser need to manually refresh (F5) this page after resetting the network.

This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.

"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.

miRNA-gene regulations

(Download full result)

Num microRNA           Gene miRNA log2FC miRNA pvalue Gene log2FC Gene pvalue Interaction Correlation beta Correlation P-value PMID Reported in cancer studies
1 hsa-miR-106a-5p BMP2 3.99 0 0.6 0.59614 miRNATAP -0.28 0.0002 NA
2 hsa-miR-362-3p BMP2 0.68 0.22615 0.6 0.59614 miRanda -0.39 0.0006 NA
3 hsa-miR-378c BMP2 0.45 0.49938 0.6 0.59614 miRNATAP -0.28 0.0034 NA
4 hsa-miR-429 BMP2 6.4 0 0.6 0.59614 miRNATAP -0.32 0.00011 NA
5 hsa-miR-125a-3p BMP7 -0.07 0.92074 2.47 0.14183 miRanda -0.6 0 NA
6 hsa-miR-30a-5p BMP7 -0.77 0.32049 2.47 0.14183 mirMAP; miRNATAP -0.84 0 NA
7 hsa-miR-338-3p BMP7 0.45 0.55849 2.47 0.14183 miRanda -0.68 0 NA
8 hsa-miR-150-5p CTNNB1 1.77 0.05938 -0.6 0.15222 MirTarget -0.12 0 NA
9 hsa-miR-155-5p CTNNB1 2.81 7.0E-5 -0.6 0.15222 miRNAWalker2 validate -0.17 0 NA
10 hsa-miR-221-3p CTNNB1 0.94 0.17475 -0.6 0.15222 miRNAWalker2 validate -0.15 1.0E-5 NA
11 hsa-miR-330-3p CTNNB1 2.49 0.00013 -0.6 0.15222 MirTarget; PITA; miRNATAP -0.11 0.00159 NA
12 hsa-miR-590-3p CTNNB1 2.35 0 -0.6 0.15222 miRanda -0.16 0.00059 NA
13 hsa-miR-15b-5p EPB41L5 3.32 0 -1.33 0.01989 MirTarget -0.21 0.00208 NA
14 hsa-miR-16-1-3p EPB41L5 2.83 0 -1.33 0.01989 mirMAP -0.18 0.00642 NA
15 hsa-miR-16-2-3p EPB41L5 3.8 0 -1.33 0.01989 mirMAP -0.26 2.0E-5 NA
16 hsa-miR-16-5p EPB41L5 2.94 0 -1.33 0.01989 MirTarget -0.21 0.00213 NA
17 hsa-miR-33b-5p EPB41L5 4.78 0 -1.33 0.01989 mirMAP -0.14 0.00023 NA
18 hsa-miR-192-5p FAM83D 1.78 0.11349 6.15 0 miRNAWalker2 validate -0.11 0.00063 NA
19 hsa-miR-146b-5p FGFR2 1.88 0.00074 -1.55 0.07059 miRanda -0.3 0.00059 NA
20 hsa-miR-330-5p FGFR2 2.25 0.00028 -1.55 0.07059 miRanda -0.39 0 NA
21 hsa-miR-338-3p FGFR2 0.45 0.55849 -1.55 0.07059 miRanda; miRNATAP -0.2 0.00168 NA
22 hsa-miR-181c-5p GSK3B -0.3 0.53753 0.98 0.00615 mirMAP -0.12 0.00582 NA
23 hsa-miR-30a-3p GSK3B -1.22 0.16757 0.98 0.00615 miRNATAP -0.12 0 NA
24 hsa-miR-30d-3p GSK3B -0.07 0.85742 0.98 0.00615 miRNATAP -0.22 1.0E-5 NA
25 hsa-miR-320c GSK3B -0.11 0.854 0.98 0.00615 miRanda; mirMAP -0.1 0.00538 NA
26 hsa-miR-362-5p GSK3B -1.22 0.04527 0.98 0.00615 miRNATAP -0.12 0.00047 NA
27 hsa-let-7f-1-3p HGF 1.62 0.00069 -3.9 9.0E-5 mirMAP -0.54 1.0E-5 NA
28 hsa-miR-141-3p HGF 7.3 0 -3.9 9.0E-5 MirTarget; TargetScan -0.41 0 NA
29 hsa-miR-200a-3p HGF 6.34 0 -3.9 9.0E-5 MirTarget -0.28 5.0E-5 NA
30 hsa-miR-203a-3p HGF 6.35 0 -3.9 9.0E-5 MirTarget -0.2 1.0E-5 NA
31 hsa-miR-335-3p HGF 1.2 0.09389 -3.9 9.0E-5 mirMAP -0.27 0.00062 NA
32 hsa-miR-33a-3p HGF 2.06 0.00156 -3.9 9.0E-5 mirMAP -0.33 0.00018 NA
33 hsa-miR-34c-5p HGF 2.65 0.01574 -3.9 9.0E-5 miRanda -0.14 0.00726 NA
34 hsa-miR-429 HGF 6.4 0 -3.9 9.0E-5 miRanda -0.32 1.0E-5 NA
35 hsa-miR-590-5p HGF 1.51 0.00239 -3.9 9.0E-5 miRanda -0.3 0.0092 NA
36 hsa-miR-651-5p HGF 2.64 3.0E-5 -3.9 9.0E-5 MirTarget -0.27 0.00294 NA
37 hsa-miR-944 HGF 7.21 0.00082 -3.9 9.0E-5 mirMAP -0.12 0.00027 NA
38 hsa-miR-28-5p HIF1A -0.82 0.02212 0.73 0.1694 miRanda -0.25 0.00323 NA
39 hsa-let-7a-5p HMGA2 0.15 0.64531 2.93 0.11125 miRNAWalker2 validate; miRTarBase; MirTarget; TargetScan -1.42 2.0E-5 20949044; 18413822; 23073586; 21598109; 24612219; 23134218; 23700794; 21412931 Since let-7 miRNAs generally play a tumor-suppressive role as targeting oncogenes such as RAS and HMGA2 our results suggest that AZ-P7a cells release let-7 miRNAs via exosomes into the extracellular environment to maintain their oncogenesis;Recent studies report that HMGA2 is negatively regulated by the let-7 microRNA miRNA family; However no studies have examined the clinical significance of HMGA2 and its relationship to the let-7 miRNA family in gastric cancer; We also did an association study comparing HMGA2 expression and let-7 miRNA family expression in gastric cancer; An inverse correlation between HMGA2 and let-7a was found in gastric cancer cell lines P = 0.08; Furthermore our findings suggest that HMGA2 is negatively regulated by the let-7 miRNA family in human gastric cancer;HMGA2 mRNA and let-7 family microRNA were detected by real time fluorescent quantitative reverse transcription polymerase chain reaction in the corresponding frozen tissues; All let-7 family members were detectable in all ovarian cancer samples and their expression were inversely correlated with HMGA2 mRNA expression r=-0.305P<0.05; The downregulation of let-7 is but not the only mechanism of HMGA2 overexpression in serous ovarian cancer;Role of microRNA let 7 and effect to HMGA2 in esophageal squamous cell carcinoma; To investigated the role of microRNA miRNA let-7 and its regulation on high mobility group A2 HMGA2 protein expression in esophageal squamous cell carcinoma ESCC; To evaluate the role of let-7 and HMGA2 cell proliferations were analyzed with synthetic let-7 mimics- or its inhibitor-transfected cells; The transcription of let-7 inversely correlated with HMGA2 protein; The present results demonstrated that let-7 and HMGA2 involved in ESCC carcinogenesis;HMGA2 is down regulated by microRNA let 7 and associated with epithelial mesenchymal transition in oesophageal squamous cell carcinomas of Kazakhs; To investigate the expression of let-7 and its regulation of high-mobility group A2 protein HMGA2 and to verify the relationship between let-7 HMGA2 and the process of epithelial-mesenchymal transition EMT in oesophageal squamous cell carcinomas OSCC of Kazakh patients; Let-7 could repress expression of HMGA2 after co-transfection with let-7 and HMGA2 P = 0.002; Moreover let-7 expression was observed less frequently P = 2.0 × 10-8 and HMGA2 expression more frequently P = 1.0 × 10-10 in OSCC than in normal adjacent tissues; and let-7 expression was observed less frequently in OSCC from Kazakh patients than in those from Han and Uygur patients P = 0.041; There was a reverse correlation between expression of let-7 and HMGA2 P = 0.018; Expression of let-7 can suppress cell proliferation by acting directly on regulation of HMGA2 in OSCC;MicroRNA let 7a inhibits the proliferation and invasion of nonsmall cell lung cancer cell line 95D by regulating K Ras and HMGA2 gene expression; K-RAS and HMGA2 mRNA levels were significantly higher in the let-7a overexpressed group than those in the let-7a inhibited group p < 0.05; However the protein levels of K-RAS and HMGA2 were significantly lower in the let-7a overexpressed group than those in the let-7a inhibited group p < 0.05; We suppose that let-7a inhibits the proliferation and invasion of the cell line 95D by regulating the translation of K-RAS and HMGA2 mRNA not the transcription of the mRNA itself;MiR-98 a member in the let-7 family acts as a negative regulator in the expression of HMGA2 high mobility group A2 oncogene and it has been shown to have a nearly 3-fold decrease in A549/DDP cells;Let 7 microRNA and HMGA2 levels of expression are not inversely linked in adipocytic tumors: analysis of 56 lipomas and liposarcomas with molecular cytogenetic data; The aim of our study was first to assess the role of HMGA2 expression in the pathogenesis of adipocytic tumors AT and second to seek a potential correlation between overexpression of HMGA2 and let-7 expression inhibition by analyzing a series of 56 benign and malignant AT with molecular cytogenetic data; We measured the levels of expression of HMGA2 mRNA and of eight members of the let-7 microRNA family using quantitative RT-PCR and expression of HMGA2 protein using immunohistochemistry; Although overexpression of both HMGA2 mRNA and protein in a majority of ordinary lipomas without HMGA2 structural rearrangement may have suggested a potential role for let-7 microRNAs we did not observe a significant link with let-7 inhibition in such cases
40 hsa-let-7b-3p HMGA2 0.59 0.20051 2.93 0.11125 mirMAP -0.7 0.00227 20949044; 18413822; 23073586; 21598109; 24612219; 23700794; 21412931 Since let-7 miRNAs generally play a tumor-suppressive role as targeting oncogenes such as RAS and HMGA2 our results suggest that AZ-P7a cells release let-7 miRNAs via exosomes into the extracellular environment to maintain their oncogenesis;Recent studies report that HMGA2 is negatively regulated by the let-7 microRNA miRNA family; However no studies have examined the clinical significance of HMGA2 and its relationship to the let-7 miRNA family in gastric cancer; We also did an association study comparing HMGA2 expression and let-7 miRNA family expression in gastric cancer; Furthermore our findings suggest that HMGA2 is negatively regulated by the let-7 miRNA family in human gastric cancer;HMGA2 mRNA and let-7 family microRNA were detected by real time fluorescent quantitative reverse transcription polymerase chain reaction in the corresponding frozen tissues; All let-7 family members were detectable in all ovarian cancer samples and their expression were inversely correlated with HMGA2 mRNA expression r=-0.305P<0.05; The downregulation of let-7 is but not the only mechanism of HMGA2 overexpression in serous ovarian cancer;Role of microRNA let 7 and effect to HMGA2 in esophageal squamous cell carcinoma; To investigated the role of microRNA miRNA let-7 and its regulation on high mobility group A2 HMGA2 protein expression in esophageal squamous cell carcinoma ESCC; To evaluate the role of let-7 and HMGA2 cell proliferations were analyzed with synthetic let-7 mimics- or its inhibitor-transfected cells; The transcription of let-7 inversely correlated with HMGA2 protein; The present results demonstrated that let-7 and HMGA2 involved in ESCC carcinogenesis;HMGA2 is down regulated by microRNA let 7 and associated with epithelial mesenchymal transition in oesophageal squamous cell carcinomas of Kazakhs; To investigate the expression of let-7 and its regulation of high-mobility group A2 protein HMGA2 and to verify the relationship between let-7 HMGA2 and the process of epithelial-mesenchymal transition EMT in oesophageal squamous cell carcinomas OSCC of Kazakh patients; Let-7 could repress expression of HMGA2 after co-transfection with let-7 and HMGA2 P = 0.002; Moreover let-7 expression was observed less frequently P = 2.0 × 10-8 and HMGA2 expression more frequently P = 1.0 × 10-10 in OSCC than in normal adjacent tissues; and let-7 expression was observed less frequently in OSCC from Kazakh patients than in those from Han and Uygur patients P = 0.041; There was a reverse correlation between expression of let-7 and HMGA2 P = 0.018; Expression of let-7 can suppress cell proliferation by acting directly on regulation of HMGA2 in OSCC;MiR-98 a member in the let-7 family acts as a negative regulator in the expression of HMGA2 high mobility group A2 oncogene and it has been shown to have a nearly 3-fold decrease in A549/DDP cells;Let 7 microRNA and HMGA2 levels of expression are not inversely linked in adipocytic tumors: analysis of 56 lipomas and liposarcomas with molecular cytogenetic data; The aim of our study was first to assess the role of HMGA2 expression in the pathogenesis of adipocytic tumors AT and second to seek a potential correlation between overexpression of HMGA2 and let-7 expression inhibition by analyzing a series of 56 benign and malignant AT with molecular cytogenetic data; We measured the levels of expression of HMGA2 mRNA and of eight members of the let-7 microRNA family using quantitative RT-PCR and expression of HMGA2 protein using immunohistochemistry; Although overexpression of both HMGA2 mRNA and protein in a majority of ordinary lipomas without HMGA2 structural rearrangement may have suggested a potential role for let-7 microRNAs we did not observe a significant link with let-7 inhibition in such cases
41 hsa-let-7b-5p HMGA2 -0.19 0.65188 2.93 0.11125 miRNAWalker2 validate; miRTarBase; MirTarget -0.96 0.00013 20949044; 18413822; 23073586; 21598109; 24612219; 23700794; 21412931 Since let-7 miRNAs generally play a tumor-suppressive role as targeting oncogenes such as RAS and HMGA2 our results suggest that AZ-P7a cells release let-7 miRNAs via exosomes into the extracellular environment to maintain their oncogenesis;Recent studies report that HMGA2 is negatively regulated by the let-7 microRNA miRNA family; However no studies have examined the clinical significance of HMGA2 and its relationship to the let-7 miRNA family in gastric cancer; We also did an association study comparing HMGA2 expression and let-7 miRNA family expression in gastric cancer; Furthermore our findings suggest that HMGA2 is negatively regulated by the let-7 miRNA family in human gastric cancer;HMGA2 mRNA and let-7 family microRNA were detected by real time fluorescent quantitative reverse transcription polymerase chain reaction in the corresponding frozen tissues; All let-7 family members were detectable in all ovarian cancer samples and their expression were inversely correlated with HMGA2 mRNA expression r=-0.305P<0.05; The downregulation of let-7 is but not the only mechanism of HMGA2 overexpression in serous ovarian cancer;Role of microRNA let 7 and effect to HMGA2 in esophageal squamous cell carcinoma; To investigated the role of microRNA miRNA let-7 and its regulation on high mobility group A2 HMGA2 protein expression in esophageal squamous cell carcinoma ESCC; To evaluate the role of let-7 and HMGA2 cell proliferations were analyzed with synthetic let-7 mimics- or its inhibitor-transfected cells; The transcription of let-7 inversely correlated with HMGA2 protein; The present results demonstrated that let-7 and HMGA2 involved in ESCC carcinogenesis;HMGA2 is down regulated by microRNA let 7 and associated with epithelial mesenchymal transition in oesophageal squamous cell carcinomas of Kazakhs; To investigate the expression of let-7 and its regulation of high-mobility group A2 protein HMGA2 and to verify the relationship between let-7 HMGA2 and the process of epithelial-mesenchymal transition EMT in oesophageal squamous cell carcinomas OSCC of Kazakh patients; Let-7 could repress expression of HMGA2 after co-transfection with let-7 and HMGA2 P = 0.002; Moreover let-7 expression was observed less frequently P = 2.0 × 10-8 and HMGA2 expression more frequently P = 1.0 × 10-10 in OSCC than in normal adjacent tissues; and let-7 expression was observed less frequently in OSCC from Kazakh patients than in those from Han and Uygur patients P = 0.041; There was a reverse correlation between expression of let-7 and HMGA2 P = 0.018; Expression of let-7 can suppress cell proliferation by acting directly on regulation of HMGA2 in OSCC;MiR-98 a member in the let-7 family acts as a negative regulator in the expression of HMGA2 high mobility group A2 oncogene and it has been shown to have a nearly 3-fold decrease in A549/DDP cells;Let 7 microRNA and HMGA2 levels of expression are not inversely linked in adipocytic tumors: analysis of 56 lipomas and liposarcomas with molecular cytogenetic data; The aim of our study was first to assess the role of HMGA2 expression in the pathogenesis of adipocytic tumors AT and second to seek a potential correlation between overexpression of HMGA2 and let-7 expression inhibition by analyzing a series of 56 benign and malignant AT with molecular cytogenetic data; We measured the levels of expression of HMGA2 mRNA and of eight members of the let-7 microRNA family using quantitative RT-PCR and expression of HMGA2 protein using immunohistochemistry; Although overexpression of both HMGA2 mRNA and protein in a majority of ordinary lipomas without HMGA2 structural rearrangement may have suggested a potential role for let-7 microRNAs we did not observe a significant link with let-7 inhibition in such cases
42 hsa-let-7c-5p HMGA2 -2.04 0.02284 2.93 0.11125 miRNAWalker2 validate; miRTarBase; MirTarget -0.47 5.0E-5 NA
43 hsa-miR-125b-2-3p HMGA2 -1.76 0.12262 2.93 0.11125 mirMAP -0.35 0.00011 NA
44 hsa-miR-142-3p HMGA2 4.35 0 2.93 0.11125 PITA; miRanda; miRNATAP -0.44 0.00283 NA
45 hsa-miR-195-3p HMGA2 -2.39 0.00019 2.93 0.11125 mirMAP -0.46 0.00496 NA
46 hsa-miR-23b-3p HMGA2 -0.58 0.19048 2.93 0.11125 mirMAP -0.67 0.00464 NA
47 hsa-miR-29b-2-5p HMGA2 -0.6 0.18954 2.93 0.11125 mirMAP -0.64 0.00557 NA
48 hsa-miR-30e-5p HMGA2 0.78 0.03467 2.93 0.11125 mirMAP -1.2 2.0E-5 NA
49 hsa-miR-342-3p HMGA2 1.31 0.02072 2.93 0.11125 miRanda -0.52 0.00441 NA
50 hsa-miR-193b-3p LEF1 1.35 0.08749 -1.07 0.21099 miRNAWalker2 validate -0.35 0 NA
51 hsa-miR-330-5p LEF1 2.25 0.00028 -1.07 0.21099 miRanda -0.4 0 NA
52 hsa-miR-148b-5p LIMS1 2.81 0 0.32 0.6375 MirTarget -0.2 0.00732 NA
53 hsa-miR-192-5p LIMS1 1.78 0.11349 0.32 0.6375 miRNAWalker2 validate; MirTarget -0.11 0.00187 NA
54 hsa-miR-215-5p LIMS1 3.67 0.00295 0.32 0.6375 miRNAWalker2 validate; MirTarget -0.11 0.0007 NA
55 hsa-miR-29b-3p LIMS1 0.67 0.23406 0.32 0.6375 MirTarget; miRNATAP -0.21 0.00269 NA
56 hsa-miR-29c-3p LIMS1 -0.41 0.52934 0.32 0.6375 MirTarget; miRNATAP -0.22 0.00019 NA
57 hsa-miR-30b-5p LIMS1 0.02 0.95322 0.32 0.6375 MirTarget -0.3 0.00196 NA
58 hsa-miR-30c-5p LIMS1 0.39 0.34861 0.32 0.6375 MirTarget -0.25 0.00972 NA
59 hsa-miR-30e-5p LIMS1 0.78 0.03467 0.32 0.6375 MirTarget -0.42 7.0E-5 NA
60 hsa-miR-3607-3p LIMS1 1.38 0.02401 0.32 0.6375 mirMAP -0.24 0.00013 NA
61 hsa-miR-590-3p LIMS1 2.35 0 0.32 0.6375 miRNAWalker2 validate; miRanda -0.21 0.00581 NA
62 hsa-let-7a-5p LOXL3 0.15 0.64531 -1.47 0.003 miRNATAP -0.24 0.00718 NA
63 hsa-let-7b-5p LOXL3 -0.19 0.65188 -1.47 0.003 miRNATAP -0.22 0.00106 NA
64 hsa-miR-101-3p NOG -1.12 0.02009 -1.22 0.35362 miRNATAP -0.59 0.00013 NA
65 hsa-miR-142-5p NOG 3.96 0 -1.22 0.35362 miRNATAP -0.52 0 NA
66 hsa-miR-129-5p NOTCH1 -2.67 0.00696 0.77 0.22007 miRNAWalker2 validate -0.11 0.00232 NA
67 hsa-miR-200b-3p NOTCH1 5.56 0 0.77 0.22007 MirTarget; TargetScan -0.13 0.00897 26012256; 23430952 Nobiletin inhibited hypoxia induced epithelial mesenchymal transition of lung cancer cells by inactivating of Notch 1 signaling and switching on miR 200b; Our findings suggest that downregulation of Notch-1 and reexpression of miR-200b by nobiletin might be a novel remedy for the therapy of lung cancer;We also found that reexpression of miR-34a and miR-200b by transfection led to reduced expression of Notch-1 resulting in the inhibition of osteosarcoma cell proliferation invasion and angiogenesis
68 hsa-miR-28-5p NOTCH1 -0.82 0.02212 0.77 0.22007 miRanda -0.3 0.00345 NA
69 hsa-miR-30a-5p NOTCH1 -0.77 0.32049 0.77 0.22007 miRNAWalker2 validate; miRTarBase; miRNATAP -0.2 1.0E-5 NA
70 hsa-miR-326 NOTCH1 1.77 0.03673 0.77 0.22007 miRNAWalker2 validate; miRTarBase -0.13 0.00292 NA
71 hsa-miR-34a-5p NOTCH1 0.83 0.04775 0.77 0.22007 miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP -0.23 0.00673 20351093; 22438124; 23140286; 24349627; 24565525; 25783790; 27082152; 23642368; 22347519; 23430952; 23902763; 21743299; 22992310; 23145211; 25623761; 23085450 MicroRNA 34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells; Computational miRNA target prediction suggested that Notch1 and Jagged1 were targets of miR-34a; By using functional assays miR-34a was demonstrated to bind to the 3' untranslated regions of Notch1 and Jagged1; Forced expression of miR-34a altered the expression of Notch1 and Jagged1 protein as well as Notch signaling as shown by the response of Hairy Enhancer of Split-1 protein to these treatments using western blot analysis;Delta tocotrienol suppresses Notch 1 pathway by upregulating miR 34a in nonsmall cell lung cancer cells; In our study using miRNA microarray we observed that downregulation of the Notch-1 pathway by delta-tocotrienol correlated with upregulation of miR-34a in nonsmall cell lung cancer cells NSCLC;We found that Re-expression forced expression of miR-34a inhibits cell growth and induces apoptosis with concomitant down-regulation of Notch-1 signaling pathway one of the target of miR-34a; Moreover treatment of PC cells with a natural compound genistein led to the up-regulation of miR-34a resulting in the down-regulation of Notch-1 which was correlated with inhibition of cell growth and induction of apoptosis;Most importantly BR-DIM intervention in PCa patients prior to radical prostatectomy showed reexpression of miR-34a which was consistent with decreased expression of AR PSA and Notch-1 in PCa tissue specimens;In addition intracellular restoration of miR-34a inhibited breast cancer cell migration via targeting Notch-1 signaling;MicroRNA 34a suppresses the breast cancer stem cell like characteristics by downregulating Notch1 pathway; In this study we verified that miR-34a directly and functionally targeted Notch1 in MCF-7 cells; We reported that miR-34a negatively regulated cell proliferation migration and invasion and breast cancer stem cell propagation by downregulating Notch1; The expression of miR-34a was negatively correlated with tumor stages metastasis and Notch1 expression in breast cancer tissues; Furthermore overexpression of miR-34a increased chemosensitivity of breast cancer cells to paclitaxel PTX by downregulating the Notch1 pathway; Taken together our results indicate that miR-34a inhibited breast cancer stemness and increased the chemosensitivity to PTX partially by downregulating the Notch1 pathway suggesting that miR-34a/Notch1 play an important role in regulating breast cancer stem cells;We showed that miR-34a as a tumor suppressor could separately reduce the stemness of BCSCs and activate the cytotoxic susceptibility of BCSCs to natural killer NK cells in vitro via down regulating the expression of Notch1 signaling molecules;Mechanistically miR-34a sequesters Notch1 mRNA to generate a sharp threshold response where a bimodal Notch signal specifies the choice between self-renewal and differentiation;Most importantly BR-DIM intervention in PCa patients prior to radical prostatectomy showed re-expression of miR-34a which was consistent with decreased expression of AR PSA and Notch-1 in PCa tissue specimens;We also found that reexpression of miR-34a and miR-200b by transfection led to reduced expression of Notch-1 resulting in the inhibition of osteosarcoma cell proliferation invasion and angiogenesis;Rhamnetin and cirsiliol induce radiosensitization and inhibition of epithelial mesenchymal transition EMT by miR 34a mediated suppression of Notch 1 expression in non small cell lung cancer cell lines; Indeed rhamnetin and cirsiliol increased the expression of tumor-suppressive microRNA miR-34a in a p53-dependent manner leading to inhibition of Notch-1 expression;MicroRNA 34a targets notch1 and inhibits cell proliferation in glioblastoma multiforme; Also we identified notch1 as a direct target gene of miR-34a; Knockdown of notch1 showed similar cellular functions as overexpression of miR-34a both in vitro and in vivo; Collectively our findings show that miR-34a is downregulated in GBM cells and inhibits GBM growth by targeting notch1;The re-expression of miR-34 led to a marked reduction in the expression of its target gene Notch-1;Inactivation of AR and Notch 1 signaling by miR 34a attenuates prostate cancer aggressiveness; We found that over-expression of miR-34a led to reduced expression of AR PSA and Notch-1; These findings suggest that the loss of miR-34a is directly linked with up-regulation of AR and Notch-1 both of which are highly expressed in PCa and thus finding innovative approaches by which miR-34a expression could be up-regulated will have a huge impact on the treatment of PCa especially for the treatment of mCRPC;miR 34a may regulate sensitivity of breast cancer cells to adriamycin via targeting Notch1; To explore the influence of miR-34a on Notch1 expression in breast cancer cells and to explore the role of miR-34a in the sensitivity of breast cancer cells to Adriamycin ADR; The expression levels of Notch1 mRNA and protein in MCF-7/ADR cells transfected with miR-34a mimics were significantly up-regulated; On the contrary the expressions of Notch1 mRNA and protein in MCF-7 cells transfected with miR-34a inhibitor were down-regulated; miR-34a negatively regulates the expression of Notch1 at both mRNA and protein levels;MicroRNA 34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting Notch1; The association of miR-34a and Notch1 was analyzed by dual-luciferase reporter assay and Notch1-siRNA technology; Real-time PCR assay was performed to test the expression of miR-34a and Notch1 in 38 selective breast cancer tissue samples; MiR-34a mimic could inhibit the luciferase activity of the construct containing wild-type 3' UTR of Notch1 in MCF-7/ADR cells; Further there was an inverse association between Notch1 and miR-34a expression in breast cancer; Dysregulation of miR-34a plays critical roles in the acquired ADR resistance of breast cancer at least in part via targeting Notch1
72 hsa-miR-429 NOTCH1 6.4 0 0.77 0.22007 MirTarget; PITA; miRanda; miRNATAP -0.12 0.00731 NA
73 hsa-miR-582-5p NOTCH1 0.69 0.44776 0.77 0.22007 PITA; miRNATAP -0.11 0.00735 NA
74 hsa-miR-92b-3p NOTCH1 1.69 0.01035 0.77 0.22007 miRNATAP -0.28 0 NA
75 hsa-miR-107 SNAI2 1.49 0.00013 -1.63 0.15195 miRanda -0.7 2.0E-5 NA
76 hsa-miR-148b-3p SNAI2 1.76 0 -1.63 0.15195 miRNAWalker2 validate -1.2 0 NA
77 hsa-miR-182-5p SNAI2 5.87 0 -1.63 0.15195 miRNAWalker2 validate; miRNATAP -0.35 2.0E-5 NA
78 hsa-miR-200b-3p SNAI2 5.56 0 -1.63 0.15195 TargetScan -0.65 0 NA
79 hsa-miR-200c-3p SNAI2 6.47 0 -1.63 0.15195 miRNATAP -0.37 0.00015 NA
80 hsa-miR-375 SNAI2 3.38 0.04499 -1.63 0.15195 miRanda -0.41 0 NA
81 hsa-miR-429 SNAI2 6.4 0 -1.63 0.15195 PITA; miRanda; miRNATAP -0.56 0 NA
82 hsa-miR-532-5p SNAI2 -0.3 0.50393 -1.63 0.15195 PITA -0.96 0 NA
83 hsa-miR-96-5p SNAI2 5.63 0 -1.63 0.15195 miRNATAP -0.46 0 NA
84 hsa-miR-342-3p SOX9 1.31 0.02072 3.97 2.0E-5 miRanda -0.36 0.0001 NA
85 hsa-miR-9-3p SOX9 1.69 0.12517 3.97 2.0E-5 miRNATAP -0.15 0.00164 NA
86 hsa-miR-141-3p TGFB2 7.3 0 -1.44 0.20815 miRNAWalker2 validate; miRTarBase; MirTarget; TargetScan; miRNATAP -0.22 0.00999 NA
87 hsa-miR-142-3p TGFB2 4.35 0 -1.44 0.20815 miRNATAP -0.24 0.0083 NA
88 hsa-miR-148b-3p TGFB2 1.76 0 -1.44 0.20815 MirTarget -0.65 0.00093 NA
89 hsa-miR-200a-3p TGFB2 6.34 0 -1.44 0.20815 MirTarget; miRNATAP -0.35 1.0E-5 25813153 Tumor suppressive microRNA 200a inhibits renal cell carcinoma development by directly targeting TGFB2; By performing quantitative real-time PCR ELISA and luciferase reporter assays transforming growth factor beta2 TGFB2 was validated as a direct target gene of miR-200a; Moreover siRNA-mediated knockdown of TGFB2 partially phenocopied the effect of miR-200a overexpression; These results suggest that miR-200a suppresses RCC development via directly targeting TGFB2 indicating that miR-200a may present a novel target for diagnostic and therapeutic strategies in RCC
90 hsa-miR-203a-3p TGFB2 6.35 0 -1.44 0.20815 MirTarget -0.27 0 NA
91 hsa-miR-2277-5p TGFB2 3.02 0.01346 -1.44 0.20815 MirTarget -0.25 0.00778 NA
92 hsa-miR-362-5p TGFB2 -1.22 0.04527 -1.44 0.20815 MirTarget -0.31 0.00298 NA
93 hsa-miR-375 TGFB2 3.38 0.04499 -1.44 0.20815 miRNAWalker2 validate -0.11 0.00303 NA
94 hsa-miR-429 TGFB2 6.4 0 -1.44 0.20815 miRNATAP -0.32 0.00013 NA
95 hsa-miR-500a-5p TGFB2 0.02 0.97396 -1.44 0.20815 mirMAP -0.33 0.00833 NA
96 hsa-miR-500b-5p TGFB2 0.02 0.9745 -1.44 0.20815 MirTarget -0.33 0.00868 NA
97 hsa-let-7b-5p TGFBR1 -0.19 0.65188 -0.51 0.32474 miRNATAP -0.24 0.00052 27234654 rs868 is contained in a let-7 miRNA binding site in the 3'UTR of TGFBR1 which might provide a functional basis for the association in MSS HNPCC; In luciferase assays the risk-associated allele for rs868 was associated with half the luciferase expression in the presence of miRNA let-7b-5p compared with protective allele suggesting more binding of let-7b-5p and less TGFBR1 expression
98 hsa-let-7c-5p TGFBR1 -2.04 0.02284 -0.51 0.32474 miRNAWalker2 validate; miRTarBase -0.14 1.0E-5 NA
99 hsa-let-7g-5p TGFBR1 0.86 0.00648 -0.51 0.32474 miRNATAP -0.27 0.0045 NA
100 hsa-miR-101-3p TGFBR1 -1.12 0.02009 -0.51 0.32474 miRNAWalker2 validate; miRNATAP -0.26 2.0E-5 NA
101 hsa-miR-101-5p TGFBR1 -1.42 0.01668 -0.51 0.32474 mirMAP -0.15 0.00278 NA
102 hsa-miR-128-3p TGFBR1 1.36 0.00408 -0.51 0.32474 miRNAWalker2 validate; miRTarBase -0.22 0.00035 NA
103 hsa-miR-200b-3p TGFBR1 5.56 0 -0.51 0.32474 mirMAP -0.25 0 20498632 Inhibition of TGFbeta receptor 1 TGFBR1 in these cells induced MET and reduction of prometastatic miR-21 but caused an increase of the miR-200 family
104 hsa-miR-3065-5p TGFBR1 2.14 0.06094 -0.51 0.32474 mirMAP -0.11 0.00039 NA
105 hsa-miR-361-5p TGFBR1 0.01 0.9852 -0.51 0.32474 miRanda; mirMAP; miRNATAP -0.24 0.00538 NA
106 hsa-miR-374a-5p TGFBR1 0.28 0.45888 -0.51 0.32474 mirMAP -0.24 0.00277 NA
107 hsa-miR-429 TGFBR1 6.4 0 -0.51 0.32474 miRanda; miRNATAP -0.22 0 NA
108 hsa-miR-452-5p TGFBR1 2.45 0.00115 -0.51 0.32474 mirMAP -0.12 0.0016 NA
109 hsa-miR-15a-5p TGFBR3 2.05 0 -4.82 0 MirTarget; miRNATAP -0.4 0.00058 NA
110 hsa-miR-15b-5p TGFBR3 3.32 0 -4.82 0 MirTarget; miRNATAP -0.31 0.0033 NA
111 hsa-miR-16-2-3p TGFBR3 3.8 0 -4.82 0 mirMAP -0.51 0 NA
112 hsa-miR-16-5p TGFBR3 2.94 0 -4.82 0 MirTarget; miRNATAP -0.4 0.00017 NA
113 hsa-miR-18a-3p TGFBR3 3.65 0 -4.82 0 MirTarget -0.28 4.0E-5 NA
114 hsa-miR-18a-5p TGFBR3 3.91 0 -4.82 0 MirTarget -0.31 4.0E-5 NA
115 hsa-miR-21-5p TGFBR3 2.65 0 -4.82 0 miRNAWalker2 validate -0.67 1.0E-5 NA
116 hsa-miR-222-5p TGFBR3 2.52 0.00142 -4.82 0 MirTarget -0.35 0 NA
117 hsa-miR-27a-3p TGFBR3 1.76 0.00022 -4.82 0 MirTarget; miRNATAP -0.35 0.00082 NA
118 hsa-miR-27b-3p TGFBR3 -0.09 0.85847 -4.82 0 MirTarget; miRNATAP -0.29 0.00314 NA
119 hsa-miR-33a-3p TGFBR3 2.06 0.00156 -4.82 0 mirMAP -0.24 0.00179 NA
120 hsa-miR-484 TGFBR3 1.79 0.00022 -4.82 0 MirTarget; miRNATAP -0.32 0.00235 NA
121 hsa-miR-590-3p TGFBR3 2.35 0 -4.82 0 MirTarget; miRanda; mirMAP -0.29 0.00403 NA
122 hsa-miR-627-5p TGFBR3 1.68 0.00697 -4.82 0 MirTarget -0.25 0.00168 NA
123 hsa-miR-944 TGFBR3 7.21 0.00082 -4.82 0 mirMAP -0.13 0 NA
124 hsa-miR-590-3p WNT11 2.35 0 -1.12 0.3996 miRanda -0.53 0.00035 NA
125 hsa-miR-107 WNT4 1.49 0.00013 0.35 0.75901 PITA; miRNATAP -0.71 1.0E-5 NA
126 hsa-miR-141-3p WNT5A 7.3 0 -0.34 0.71496 TargetScan -0.19 0.0057 NA
127 hsa-miR-15b-3p WNT5A 3.58 0 -0.34 0.71496 mirMAP -0.24 0.00864 NA
128 hsa-miR-16-2-3p WNT5A 3.8 0 -0.34 0.71496 MirTarget; mirMAP -0.31 0.00135 NA
129 hsa-miR-16-5p WNT5A 2.94 0 -0.34 0.71496 miRNAWalker2 validate -0.29 0.00829 NA
130 hsa-miR-2110 WNT5A 1.81 0.00137 -0.34 0.71496 MirTarget -0.3 0.00123 NA
131 hsa-miR-30c-5p WNT5A 0.39 0.34861 -0.34 0.71496 mirMAP -0.37 0.00377 NA
132 hsa-miR-30d-3p WNT5A -0.07 0.85742 -0.34 0.71496 mirMAP -0.44 0.00056 NA
133 hsa-miR-30d-5p WNT5A 0.3 0.38019 -0.34 0.71496 mirMAP -0.42 0.00692 NA
134 hsa-miR-30e-5p WNT5A 0.78 0.03467 -0.34 0.71496 mirMAP -0.39 0.00599 NA
135 hsa-miR-330-5p WNT5A 2.25 0.00028 -0.34 0.71496 miRanda -0.32 0.00013 NA
136 hsa-miR-582-5p WNT5A 0.69 0.44776 -0.34 0.71496 miRNATAP -0.18 0.00222 NA
137 hsa-miR-616-5p WNT5A 2.48 0.00318 -0.34 0.71496 mirMAP -0.28 0.00031 NA
138 hsa-miR-92a-3p WNT5A 1.88 1.0E-5 -0.34 0.71496 miRNAWalker2 validate -0.49 4.0E-5 NA

Over-represented Gene Ontology Biological Process

NumGOOverlapSizeP ValueAdj. P Value
1 EPITHELIAL TO MESENCHYMAL TRANSITION 23 56 9.885e-62 4.6e-58
2 MESENCHYMAL CELL DIFFERENTIATION 23 134 1.365e-51 3.175e-48
3 MESENCHYME DEVELOPMENT 23 190 7.772e-48 9.041e-45
4 STEM CELL DIFFERENTIATION 23 190 7.772e-48 9.041e-45
5 CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION 23 513 1.574e-37 1.465e-34
6 CELLULAR COMPONENT MORPHOGENESIS 23 900 8.059e-32 6.25e-29
7 CELL DEVELOPMENT 23 1426 3.541e-27 2.354e-24
8 TISSUE DEVELOPMENT 23 1518 1.508e-26 8.769e-24
9 RESPONSE TO GROWTH FACTOR 18 475 1.268e-25 6.554e-23
10 GLAND DEVELOPMENT 16 395 8.564e-23 3.985e-20
11 TISSUE MORPHOGENESIS 17 533 1.168e-22 4.942e-20
12 REGULATION OF OSSIFICATION 13 178 1.492e-21 5.787e-19
13 REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS 19 1021 1.757e-21 6.29e-19
14 ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS 18 957 3.976e-20 1.321e-17
15 MESENCHYME MORPHOGENESIS 9 38 9.287e-20 2.701e-17
16 REGULATION OF ORGAN MORPHOGENESIS 13 242 8.86e-20 2.701e-17
17 CELLULAR RESPONSE TO ENDOGENOUS STIMULUS 18 1008 1.008e-19 2.758e-17
18 REGULATION OF STEM CELL DIFFERENTIATION 11 113 1.452e-19 3.754e-17
19 ORGAN MORPHOGENESIS 17 841 2.735e-19 6.697e-17
20 REGULATION OF EPITHELIAL CELL PROLIFERATION 13 285 7.654e-19 1.781e-16
21 MORPHOGENESIS OF AN EPITHELIUM 14 400 9.072e-19 1.985e-16
22 POSITIVE REGULATION OF DEVELOPMENTAL PROCESS 18 1142 9.384e-19 1.985e-16
23 REGULATION OF CELL DIFFERENTIATION 19 1492 2.274e-18 4.601e-16
24 REGULATION OF CELL PROLIFERATION 19 1496 2.392e-18 4.637e-16
25 CELLULAR RESPONSE TO ORGANIC SUBSTANCE 20 1848 2.525e-18 4.699e-16
26 TUBE MORPHOGENESIS 13 323 3.955e-18 6.816e-16
27 REGULATION OF CELLULAR COMPONENT MOVEMENT 16 771 3.894e-18 6.816e-16
28 REGULATION OF CARTILAGE DEVELOPMENT 9 63 1.327e-17 2.206e-15
29 REGULATION OF CELL DEVELOPMENT 16 836 1.407e-17 2.258e-15
30 NEGATIVE REGULATION OF RESPONSE TO STIMULUS 18 1360 2.107e-17 3.268e-15
31 NEGATIVE REGULATION OF CELL DEATH 16 872 2.746e-17 4.121e-15
32 EMBRYO DEVELOPMENT 16 894 4.074e-17 5.924e-15
33 POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION 17 1152 5.484e-17 7.732e-15
34 EMBRYONIC MORPHOGENESIS 14 539 5.904e-17 8.08e-15
35 RESPONSE TO ENDOGENOUS STIMULUS 18 1450 6.573e-17 8.738e-15
36 EMBRYONIC ORGAN DEVELOPMENT 13 406 7.821e-17 1.011e-14
37 TUBE DEVELOPMENT 14 552 8.23e-17 1.035e-14
38 REGULATION OF CELL DEATH 18 1472 8.585e-17 1.051e-14
39 NEGATIVE REGULATION OF CELL COMMUNICATION 17 1192 9.719e-17 1.16e-14
40 UROGENITAL SYSTEM DEVELOPMENT 12 299 1.168e-16 1.358e-14
41 HEART MORPHOGENESIS 11 212 1.769e-16 2.008e-14
42 NEGATIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS 16 983 1.826e-16 2.023e-14
43 REGULATION OF STEM CELL PROLIFERATION 9 88 3.154e-16 3.413e-14
44 SKELETAL SYSTEM DEVELOPMENT 13 455 3.433e-16 3.619e-14
45 NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS 15 801 3.5e-16 3.619e-14
46 POSITIVE REGULATION OF STEM CELL DIFFERENTIATION 8 50 4.037e-16 4.084e-14
47 POSITIVE REGULATION OF CELL DIFFERENTIATION 15 823 5.228e-16 5.176e-14
48 REGULATION OF CANONICAL WNT SIGNALING PATHWAY 11 236 5.836e-16 5.657e-14
49 NEGATIVE REGULATION OF CARTILAGE DEVELOPMENT 7 26 6.272e-16 5.956e-14
50 REGULATION OF MORPHOGENESIS OF A BRANCHING STRUCTURE 8 53 6.651e-16 6.19e-14
51 REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT 18 1672 8.182e-16 7.465e-14
52 NEGATIVE REGULATION OF CANONICAL WNT SIGNALING PATHWAY 10 162 9.595e-16 8.586e-14
53 CELL PROLIFERATION 14 672 1.264e-15 1.109e-13
54 LOCOMOTION 16 1114 1.31e-15 1.109e-13
55 MORPHOGENESIS OF A BRANCHING STRUCTURE 10 167 1.308e-15 1.109e-13
56 POSITIVE REGULATION OF GENE EXPRESSION 18 1733 1.54e-15 1.28e-13
57 FORMATION OF PRIMARY GERM LAYER 9 110 2.528e-15 2.063e-13
58 REGULATION OF OSTEOBLAST DIFFERENTIATION 9 112 2.987e-15 2.396e-13
59 EPITHELIUM DEVELOPMENT 15 945 4.031e-15 3.179e-13
60 NEGATIVE REGULATION OF GENE EXPRESSION 17 1493 4.174e-15 3.237e-13
61 MESODERM MORPHOGENESIS 8 66 4.273e-15 3.259e-13
62 REGULATION OF BINDING 11 283 4.362e-15 3.273e-13
63 CONNECTIVE TISSUE DEVELOPMENT 10 194 5.988e-15 4.423e-13
64 POSITIVE REGULATION OF LOCOMOTION 12 420 6.908e-15 5.007e-13
65 NEGATIVE REGULATION OF WNT SIGNALING PATHWAY 10 197 6.994e-15 5.007e-13
66 KIDNEY EPITHELIUM DEVELOPMENT 9 125 8.245e-15 5.813e-13
67 MOVEMENT OF CELL OR SUBCELLULAR COMPONENT 16 1275 1.089e-14 7.562e-13
68 REGULATION OF WNT SIGNALING PATHWAY 11 310 1.191e-14 8.151e-13
69 BRANCHING MORPHOGENESIS OF AN EPITHELIAL TUBE 9 131 1.27e-14 8.564e-13
70 POSITIVE REGULATION OF CELL PROLIFERATION 14 814 1.783e-14 1.185e-12
71 REGULATION OF CELL ADHESION 13 629 2.233e-14 1.464e-12
72 HEART DEVELOPMENT 12 466 2.385e-14 1.541e-12
73 CELL MOTILITY 14 835 2.53e-14 1.591e-12
74 LOCALIZATION OF CELL 14 835 2.53e-14 1.591e-12
75 POSITIVE REGULATION OF CELL DEVELOPMENT 12 472 2.777e-14 1.723e-12
76 CELL FATE COMMITMENT 10 227 2.925e-14 1.79e-12
77 NEGATIVE REGULATION OF CELL PROLIFERATION 13 643 2.962e-14 1.79e-12
78 CARTILAGE DEVELOPMENT 9 147 3.659e-14 2.183e-12
79 POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS 16 1395 4.439e-14 2.614e-12
80 SENSORY ORGAN DEVELOPMENT 12 493 4.66e-14 2.71e-12
81 NEURON DIFFERENTIATION 14 874 4.737e-14 2.721e-12
82 NEUROGENESIS 16 1402 4.799e-14 2.723e-12
83 EPITHELIAL CELL DIFFERENTIATION 12 495 4.889e-14 2.741e-12
84 POSITIVE REGULATION OF EPITHELIAL CELL PROLIFERATION 9 154 5.601e-14 3.103e-12
85 MESONEPHROS DEVELOPMENT 8 90 5.675e-14 3.107e-12
86 GASTRULATION 9 155 5.942e-14 3.215e-12
87 DIGESTIVE TRACT MORPHOGENESIS 7 48 6.913e-14 3.697e-12
88 POSITIVE REGULATION OF BIOSYNTHETIC PROCESS 17 1805 9.703e-14 5.13e-12
89 GLAND MORPHOGENESIS 8 97 1.053e-13 5.506e-12
90 CARDIAC EPITHELIAL TO MESENCHYMAL TRANSITION 6 24 1.51e-13 7.805e-12
91 NEGATIVE REGULATION OF NITROGEN COMPOUND METABOLIC PROCESS 16 1517 1.637e-13 8.372e-12
92 EMBRYO DEVELOPMENT ENDING IN BIRTH OR EGG HATCHING 12 554 1.858e-13 9.397e-12
93 EMBRYONIC ORGAN MORPHOGENESIS 10 279 2.317e-13 1.159e-11
94 PATTERN SPECIFICATION PROCESS 11 418 3.148e-13 1.558e-11
95 COLUMNAR CUBOIDAL EPITHELIAL CELL DIFFERENTIATION 8 111 3.187e-13 1.561e-11
96 CARDIOVASCULAR SYSTEM DEVELOPMENT 13 788 3.974e-13 1.906e-11
97 CIRCULATORY SYSTEM DEVELOPMENT 13 788 3.974e-13 1.906e-11
98 POSITIVE REGULATION OF STEM CELL PROLIFERATION 7 61 4.059e-13 1.927e-11
99 NEPHRON DEVELOPMENT 8 115 4.258e-13 2.001e-11
100 MESODERM DEVELOPMENT 8 118 5.256e-13 2.446e-11
101 NEGATIVE REGULATION OF CELL DIFFERENTIATION 12 609 5.684e-13 2.619e-11
102 REGULATION OF EPITHELIAL TO MESENCHYMAL TRANSITION 7 67 8.057e-13 3.676e-11
103 MORPHOGENESIS OF EMBRYONIC EPITHELIUM 8 134 1.481e-12 6.691e-11
104 POSITIVE REGULATION OF EPITHELIAL TO MESENCHYMAL TRANSITION 6 34 1.498e-12 6.7e-11
105 REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION 10 337 1.522e-12 6.743e-11
106 REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS 9 229 2.055e-12 9.019e-11
107 RENAL TUBULE DEVELOPMENT 7 78 2.429e-12 1.056e-10
108 RESPONSE TO TRANSFORMING GROWTH FACTOR BETA 8 144 2.656e-12 1.144e-10
109 FOREBRAIN DEVELOPMENT 10 357 2.697e-12 1.151e-10
110 DIGESTIVE SYSTEM DEVELOPMENT 8 148 3.317e-12 1.403e-10
111 POSITIVE REGULATION OF OSSIFICATION 7 84 4.147e-12 1.738e-10
112 POSITIVE REGULATION OF CELL COMMUNICATION 15 1532 4.678e-12 1.944e-10
113 PROSTATE GLAND DEVELOPMENT 6 41 4.981e-12 2.051e-10
114 POSITIVE REGULATION OF RESPONSE TO STIMULUS 16 1929 6.715e-12 2.741e-10
115 POSITIVE REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION 8 162 6.886e-12 2.786e-10
116 REGULATION OF CELLULAR COMPONENT BIOGENESIS 12 767 8.524e-12 3.392e-10
117 POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 13 1004 8.529e-12 3.392e-10
118 NEPHRON EPITHELIUM DEVELOPMENT 7 93 8.619e-12 3.399e-10
119 REGULATION OF PROTEIN BINDING 8 168 9.233e-12 3.61e-10
120 APPENDAGE DEVELOPMENT 8 169 9.685e-12 3.724e-10
121 LIMB DEVELOPMENT 8 169 9.685e-12 3.724e-10
122 CANONICAL WNT SIGNALING PATHWAY 7 95 1.004e-11 3.821e-10
123 REPRODUCTIVE SYSTEM DEVELOPMENT 10 408 1.01e-11 3.821e-10
124 GROWTH 10 410 1.06e-11 3.978e-10
125 REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 15 1656 1.437e-11 5.351e-10
126 POSITIVE REGULATION OF CELL DEATH 11 605 1.724e-11 6.368e-10
127 MUSCLE STRUCTURE DEVELOPMENT 10 432 1.774e-11 6.501e-10
128 MESONEPHRIC TUBULE MORPHOGENESIS 6 53 2.521e-11 9.165e-10
129 REGULATION OF GROWTH 11 633 2.803e-11 1.011e-09
130 ANTERIOR POSTERIOR PATTERN SPECIFICATION 8 194 2.935e-11 1.051e-09
131 IN UTERO EMBRYONIC DEVELOPMENT 9 311 3.197e-11 1.127e-09
132 REGIONALIZATION 9 311 3.197e-11 1.127e-09
133 ENDOCARDIAL CUSHION MORPHOGENESIS 5 22 3.282e-11 1.148e-09
134 RESPIRATORY SYSTEM DEVELOPMENT 8 197 3.32e-11 1.153e-09
135 NEGATIVE REGULATION OF EPITHELIAL CELL PROLIFERATION 7 115 3.925e-11 1.353e-09
136 REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 15 1784 4.188e-11 1.433e-09
137 RESPONSE TO LIPID 12 888 4.694e-11 1.594e-09
138 REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY 8 207 4.935e-11 1.664e-09
139 STEM CELL PROLIFERATION 6 60 5.47e-11 1.831e-09
140 EMBRYONIC SKELETAL SYSTEM DEVELOPMENT 7 122 5.971e-11 1.984e-09
141 ENDOCRINE SYSTEM DEVELOPMENT 7 123 6.327e-11 2.088e-09
142 REGULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR SIGNALING PATHWAY 5 25 6.608e-11 2.165e-09
143 REGULATION OF REPRODUCTIVE PROCESS 7 129 8.866e-11 2.865e-09
144 TUBE FORMATION 7 129 8.866e-11 2.865e-09
145 HEAD DEVELOPMENT 11 709 9.435e-11 3.028e-09
146 REGULATION OF CELL CYCLE 12 949 1.014e-10 3.23e-09
147 REGULATION OF APOPTOTIC SIGNALING PATHWAY 9 363 1.265e-10 4.003e-09
148 REGULATION OF HEART MORPHOGENESIS 5 29 1.472e-10 4.629e-09
149 REGULATION OF CELL MORPHOGENESIS 10 552 1.96e-10 6.119e-09
150 REGULATION OF PHOSPHORUS METABOLIC PROCESS 14 1618 1.982e-10 6.149e-09
151 OSSIFICATION 8 251 2.294e-10 7.069e-09
152 ENDOCARDIAL CUSHION DEVELOPMENT 5 32 2.491e-10 7.576e-09
153 REGULATION OF ORGAN FORMATION 5 32 2.491e-10 7.576e-09
154 POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS 12 1036 2.789e-10 8.373e-09
155 POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS 12 1036 2.789e-10 8.373e-09
156 POSITIVE REGULATION OF CELLULAR COMPONENT BIOGENESIS 9 406 3.406e-10 1.016e-08
157 REGULATION OF MESENCHYMAL CELL PROLIFERATION 5 34 3.437e-10 1.019e-08
158 KIDNEY MORPHOGENESIS 6 82 3.765e-10 1.109e-08
159 REGULATION OF PROTEIN MODIFICATION PROCESS 14 1710 4.136e-10 1.21e-08
160 DEVELOPMENTAL PROCESS INVOLVED IN REPRODUCTION 10 602 4.556e-10 1.325e-08
161 PALATE DEVELOPMENT 6 85 4.692e-10 1.356e-08
162 GLANDULAR EPITHELIAL CELL DIFFERENTIATION 5 39 7.086e-10 2.035e-08
163 POSITIVE REGULATION OF MOLECULAR FUNCTION 14 1791 7.638e-10 2.18e-08
164 POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS 12 1135 7.955e-10 2.257e-08
165 CENTRAL NERVOUS SYSTEM DEVELOPMENT 11 872 8.499e-10 2.397e-08
166 PATHWAY RESTRICTED SMAD PROTEIN PHOSPHORYLATION 4 13 9.435e-10 2.629e-08
167 MESENCHYMAL CELL PROLIFERATION 4 13 9.435e-10 2.629e-08
168 RESPONSE TO EXTERNAL STIMULUS 14 1821 9.515e-10 2.635e-08
169 NEGATIVE REGULATION OF CELL DEVELOPMENT 8 303 1.019e-09 2.804e-08
170 REGULATION OF MAPK CASCADE 10 660 1.111e-09 3.04e-08
171 EPITHELIAL CELL DEVELOPMENT 7 186 1.162e-09 3.161e-08
172 POSITIVE REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY 6 100 1.265e-09 3.422e-08
173 TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY 7 190 1.348e-09 3.625e-08
174 REGULATION OF MUSCLE TISSUE DEVELOPMENT 6 103 1.514e-09 4.025e-08
175 REGULATION OF MUSCLE ORGAN DEVELOPMENT 6 103 1.514e-09 4.025e-08
176 CARDIAC CHAMBER MORPHOGENESIS 6 104 1.605e-09 4.22e-08
177 DEVELOPMENTAL GROWTH INVOLVED IN MORPHOGENESIS 6 104 1.605e-09 4.22e-08
178 ENZYME LINKED RECEPTOR PROTEIN SIGNALING PATHWAY 10 689 1.683e-09 4.398e-08
179 ODONTOGENESIS 6 105 1.701e-09 4.423e-08
180 CARDIAC VENTRICLE DEVELOPMENT 6 106 1.802e-09 4.659e-08
181 NEGATIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY 7 200 1.927e-09 4.954e-08
182 SKELETAL SYSTEM MORPHOGENESIS 7 201 1.995e-09 5.101e-08
183 DEVELOPMENTAL GROWTH 8 333 2.142e-09 5.447e-08
184 PARAXIAL MESODERM DEVELOPMENT 4 16 2.396e-09 6.059e-08
185 SKIN DEVELOPMENT 7 211 2.797e-09 7.035e-08
186 MAMMARY GLAND DEVELOPMENT 6 117 3.278e-09 8.2e-08
187 NEGATIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 10 740 3.347e-09 8.327e-08
188 REGULATION OF NERVOUS SYSTEM DEVELOPMENT 10 750 3.807e-09 9.423e-08
189 CARDIAC MUSCLE TISSUE MORPHOGENESIS 5 54 3.848e-09 9.474e-08
190 NEGATIVE REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS 6 121 4.016e-09 9.8e-08
191 NOTOCHORD DEVELOPMENT 4 18 4.023e-09 9.8e-08
192 REGULATION OF KIDNEY DEVELOPMENT 5 55 4.23e-09 1.025e-07
193 BLOOD VESSEL MORPHOGENESIS 8 364 4.307e-09 1.038e-07
194 RESPONSE TO ABIOTIC STIMULUS 11 1024 4.606e-09 1.105e-07
195 POSITIVE REGULATION OF BINDING 6 127 5.378e-09 1.283e-07
196 POSITIVE REGULATION OF CELL ADHESION 8 376 5.552e-09 1.308e-07
197 EMBRYONIC PATTERN SPECIFICATION 5 58 5.559e-09 1.308e-07
198 REGULATION OF VASCULATURE DEVELOPMENT 7 233 5.567e-09 1.308e-07
199 HEPATICOBILIARY SYSTEM DEVELOPMENT 6 128 5.639e-09 1.318e-07
200 REGULATION OF CELL CELL ADHESION 8 380 6.031e-09 1.403e-07
201 MUSCLE CELL DIFFERENTIATION 7 237 6.264e-09 1.45e-07
202 NEGATIVE REGULATION OF CHONDROCYTE DIFFERENTIATION 4 20 6.359e-09 1.465e-07
203 REGULATION OF PATHWAY RESTRICTED SMAD PROTEIN PHOSPHORYLATION 5 60 6.616e-09 1.507e-07
204 POSITIVE REGULATION OF OSTEOBLAST DIFFERENTIATION 5 60 6.616e-09 1.507e-07
205 SENSORY ORGAN MORPHOGENESIS 7 239 6.639e-09 1.507e-07
206 IMMUNE SYSTEM DEVELOPMENT 9 582 7.989e-09 1.804e-07
207 NEUROEPITHELIAL CELL DIFFERENTIATION 5 63 8.496e-09 1.91e-07
208 SOMATIC STEM CELL DIVISION 4 22 9.587e-09 2.145e-07
209 CARDIAC MUSCLE TISSUE DEVELOPMENT 6 140 9.668e-09 2.152e-07
210 CARDIAC CHAMBER DEVELOPMENT 6 144 1.145e-08 2.537e-07
211 PROSTATE GLAND MORPHOGENESIS 4 23 1.16e-08 2.557e-07
212 NEGATIVE REGULATION OF NERVOUS SYSTEM DEVELOPMENT 7 262 1.253e-08 2.742e-07
213 ORGAN GROWTH 5 68 1.255e-08 2.742e-07
214 MUSCLE ORGAN MORPHOGENESIS 5 70 1.455e-08 3.164e-07
215 SKIN EPIDERMIS DEVELOPMENT 5 71 1.564e-08 3.37e-07
216 ENDODERM DEVELOPMENT 5 71 1.564e-08 3.37e-07
217 POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 10 876 1.68e-08 3.603e-07
218 AMEBOIDAL TYPE CELL MIGRATION 6 154 1.712e-08 3.655e-07
219 MUSCLE TISSUE DEVELOPMENT 7 275 1.749e-08 3.715e-07
220 POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS 12 1492 1.772e-08 3.748e-07
221 POSITIVE REGULATION OF NERVOUS SYSTEM DEVELOPMENT 8 437 1.792e-08 3.774e-07
222 EMBRYONIC HEART TUBE DEVELOPMENT 5 73 1.802e-08 3.777e-07
223 REGULATION OF BIOMINERAL TISSUE DEVELOPMENT 5 75 2.067e-08 4.314e-07
224 POSITIVE REGULATION OF CATALYTIC ACTIVITY 12 1518 2.152e-08 4.469e-07
225 DEVELOPMENTAL INDUCTION 4 27 2.291e-08 4.697e-07
226 POSITIVE REGULATION OF MESENCHYMAL CELL PROLIFERATION 4 27 2.291e-08 4.697e-07
227 AXIS ELONGATION 4 27 2.291e-08 4.697e-07
228 DIENCEPHALON DEVELOPMENT 5 77 2.363e-08 4.823e-07
229 SOMITE DEVELOPMENT 5 78 2.523e-08 5.126e-07
230 RESPONSE TO ORGANIC CYCLIC COMPOUND 10 917 2.595e-08 5.249e-07
231 VENTRICULAR SEPTUM MORPHOGENESIS 4 28 2.671e-08 5.379e-07
232 REGULATION OF EPITHELIAL CELL MIGRATION 6 166 2.682e-08 5.379e-07
233 ANGIOGENESIS 7 293 2.704e-08 5.4e-07
234 EPIDERMIS MORPHOGENESIS 4 29 3.096e-08 6.113e-07
235 STEM CELL DIVISION 4 29 3.096e-08 6.113e-07
236 VASCULATURE DEVELOPMENT 8 469 3.101e-08 6.113e-07
237 PROTEIN PHOSPHORYLATION 10 944 3.416e-08 6.707e-07
238 HAIR CYCLE 5 83 3.457e-08 6.73e-07
239 MOLTING CYCLE 5 83 3.457e-08 6.73e-07
240 REGULATION OF CELLULAR RESPONSE TO STRESS 9 691 3.525e-08 6.834e-07
241 SMOOTH MUSCLE CELL DIFFERENTIATION 4 30 3.57e-08 6.892e-07
242 RESPONSE TO OXYGEN LEVELS 7 311 4.069e-08 7.824e-07
243 RESPONSE TO STEROID HORMONE 8 497 4.854e-08 9.295e-07
244 REPRODUCTION 11 1297 5.354e-08 1.021e-06
245 EYE DEVELOPMENT 7 326 5.617e-08 1.067e-06
246 HEART VALVE DEVELOPMENT 4 34 6.023e-08 1.139e-06
247 EMBRYONIC SKELETAL SYSTEM MORPHOGENESIS 5 93 6.142e-08 1.157e-06
248 POSITIVE REGULATION OF CELL CYCLE 7 332 6.362e-08 1.194e-06
249 RESPONSE TO BMP 5 94 6.482e-08 1.206e-06
250 CELLULAR RESPONSE TO BMP STIMULUS 5 94 6.482e-08 1.206e-06
251 EAR DEVELOPMENT 6 195 6.994e-08 1.297e-06
252 NEGATIVE REGULATION OF EPITHELIAL CELL DIFFERENTIATION 4 37 8.558e-08 1.58e-06
253 WNT SIGNALING PATHWAY 7 351 9.299e-08 1.704e-06
254 CAMERA TYPE EYE MORPHOGENESIS 5 101 9.304e-08 1.704e-06
255 NEGATIVE REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY 5 102 9.776e-08 1.784e-06
256 RESPONSE TO OXYGEN CONTAINING COMPOUND 11 1381 1.019e-07 1.853e-06
257 POSITIVE REGULATION OF EPITHELIAL CELL MIGRATION 5 103 1.027e-07 1.859e-06
258 WNT SIGNALING PATHWAY CALCIUM MODULATING PATHWAY 4 39 1.064e-07 1.919e-06
259 REGULATION OF NEURON DIFFERENTIATION 8 554 1.12e-07 2.011e-06
260 POSITIVE REGULATION OF CELL MATRIX ADHESION 4 40 1.181e-07 2.109e-06
261 REGULATION OF CELL CYCLE PROCESS 8 558 1.183e-07 2.109e-06
262 REGULATION OF CYTOKINE PRODUCTION 8 563 1.267e-07 2.25e-06
263 CELL MORPHOGENESIS INVOLVED IN NEURON DIFFERENTIATION 7 368 1.283e-07 2.27e-06
264 PITUITARY GLAND DEVELOPMENT 4 42 1.445e-07 2.546e-06
265 REGULATION OF EMBRYONIC DEVELOPMENT 5 114 1.708e-07 2.998e-06
266 BRANCHING INVOLVED IN URETERIC BUD MORPHOGENESIS 4 44 1.75e-07 3.06e-06
267 TELENCEPHALON DEVELOPMENT 6 228 1.764e-07 3.074e-06
268 LUNG MORPHOGENESIS 4 45 1.919e-07 3.319e-06
269 EXOCRINE SYSTEM DEVELOPMENT 4 45 1.919e-07 3.319e-06
270 REGULATION OF CHONDROCYTE DIFFERENTIATION 4 46 2.1e-07 3.619e-06
271 EPITHELIAL CELL DIFFERENTIATION INVOLVED IN PROSTATE GLAND DEVELOPMENT 3 11 2.179e-07 3.741e-06
272 POSITIVE REGULATION OF GROWTH 6 238 2.272e-07 3.887e-06
273 NEURON PROJECTION MORPHOGENESIS 7 402 2.336e-07 3.982e-06
274 REGULATION OF CARDIAC MUSCLE TISSUE DEVELOPMENT 4 48 2.5e-07 4.23e-06
275 POSITIVE REGULATION OF PATHWAY RESTRICTED SMAD PROTEIN PHOSPHORYLATION 4 48 2.5e-07 4.23e-06
276 CARDIAC SEPTUM MORPHOGENESIS 4 49 2.72e-07 4.586e-06
277 REGULATION OF ORGANELLE ORGANIZATION 10 1178 2.733e-07 4.591e-06
278 OSTEOBLAST DIFFERENTIATION 5 126 2.815e-07 4.712e-06
279 REGULATION OF MESENCHYMAL CELL APOPTOTIC PROCESS 3 12 2.903e-07 4.841e-06
280 FACE DEVELOPMENT 4 50 2.955e-07 4.91e-06
281 RESPONSE TO HORMONE 9 893 3.145e-07 5.208e-06
282 EPIDERMIS DEVELOPMENT 6 253 3.255e-07 5.371e-06
283 NEGATIVE REGULATION OF BINDING 5 131 3.418e-07 5.619e-06
284 POSITIVE REGULATION OF REPRODUCTIVE PROCESS 4 52 3.468e-07 5.682e-06
285 MAMMARY GLAND EPITHELIUM DEVELOPMENT 4 53 3.748e-07 6.12e-06
286 PHOSPHORYLATION 10 1228 4.021e-07 6.542e-06
287 VENTRICULAR SEPTUM DEVELOPMENT 4 54 4.045e-07 6.558e-06
288 NEGATIVE REGULATION OF LOCOMOTION 6 263 4.087e-07 6.602e-06
289 EYE MORPHOGENESIS 5 136 4.118e-07 6.63e-06
290 OUTFLOW TRACT MORPHOGENESIS 4 56 4.691e-07 7.526e-06
291 NON CANONICAL WNT SIGNALING PATHWAY 5 140 4.756e-07 7.605e-06
292 CELL MIGRATION INVOLVED IN GASTRULATION 3 14 4.796e-07 7.616e-06
293 EMBRYONIC SKELETAL JOINT DEVELOPMENT 3 14 4.796e-07 7.616e-06
294 REGULATION OF TRANSFERASE ACTIVITY 9 946 5.116e-07 8.097e-06
295 REGULATION OF PROTEIN LOCALIZATION 9 950 5.301e-07 8.361e-06
296 CELLULAR RESPONSE TO LIPID 7 457 5.548e-07 8.721e-06
297 ACTIVATION OF PROTEIN KINASE ACTIVITY 6 279 5.775e-07 9.048e-06
298 REGULATION OF GLIAL CELL DIFFERENTIATION 4 59 5.799e-07 9.055e-06
299 RESPONSE TO ESTRADIOL 5 146 5.858e-07 9.116e-06
300 MORPHOGENESIS OF AN EPITHELIAL FOLD 3 15 5.99e-07 9.229e-06
301 REGULATION OF CELL PROLIFERATION INVOLVED IN HEART MORPHOGENESIS 3 15 5.99e-07 9.229e-06
302 STRIATED MUSCLE CELL PROLIFERATION 3 15 5.99e-07 9.229e-06
303 MALE SEX DIFFERENTIATION 5 148 6.266e-07 9.623e-06
304 EMBRYONIC DIGIT MORPHOGENESIS 4 61 6.639e-07 1.016e-05
305 POSITIVE REGULATION OF MAPK CASCADE 7 470 6.698e-07 1.022e-05
306 CARDIAC VENTRICLE MORPHOGENESIS 4 62 7.092e-07 1.078e-05
307 REGULATION OF MUSCLE CELL DIFFERENTIATION 5 152 7.152e-07 1.084e-05
308 CELL SURFACE RECEPTOR SIGNALING PATHWAY INVOLVED IN HEART DEVELOPMENT 3 16 7.367e-07 1.113e-05
309 REGULATION OF HYDROLASE ACTIVITY 10 1327 8.231e-07 1.239e-05
310 BRANCH ELONGATION OF AN EPITHELIUM 3 17 8.939e-07 1.333e-05
311 NEGATIVE REGULATION OF ALCOHOL BIOSYNTHETIC PROCESS 3 17 8.939e-07 1.333e-05
312 NEGATIVE REGULATION OF STEM CELL PROLIFERATION 3 17 8.939e-07 1.333e-05
313 REGULATION OF CELL JUNCTION ASSEMBLY 4 68 1.031e-06 1.527e-05
314 POSITIVE REGULATION OF ENDOTHELIAL CELL PROLIFERATION 4 68 1.031e-06 1.527e-05
315 REGULATION OF HORMONE BIOSYNTHETIC PROCESS 3 18 1.072e-06 1.573e-05
316 PERICARDIUM DEVELOPMENT 3 18 1.072e-06 1.573e-05
317 NEPHRON TUBULE FORMATION 3 18 1.072e-06 1.573e-05
318 NEGATIVE REGULATION OF OSSIFICATION 4 69 1.093e-06 1.6e-05
319 RESPONSE TO ACID CHEMICAL 6 319 1.262e-06 1.834e-05
320 REGULATION OF MAP KINASE ACTIVITY 6 319 1.262e-06 1.834e-05
321 MUSCLE CELL PROLIFERATION 3 19 1.272e-06 1.844e-05
322 CELL CELL SIGNALING 8 767 1.325e-06 1.915e-05
323 MULTICELLULAR ORGANISM REPRODUCTION 8 768 1.338e-06 1.928e-05
324 REGULATION OF CELL SUBSTRATE ADHESION 5 173 1.355e-06 1.947e-05
325 POSITIVE REGULATION OF PROTEIN BINDING 4 73 1.372e-06 1.959e-05
326 REGULATION OF NEURAL PRECURSOR CELL PROLIFERATION 4 73 1.372e-06 1.959e-05
327 GLIOGENESIS 5 175 1.434e-06 2.041e-05
328 REGULATION OF KINASE ACTIVITY 8 776 1.447e-06 2.052e-05
329 TRACHEA DEVELOPMENT 3 20 1.495e-06 2.115e-05
330 PROTEIN LOCALIZATION 11 1805 1.524e-06 2.144e-05
331 ODONTOGENESIS OF DENTIN CONTAINING TOOTH 4 75 1.53e-06 2.144e-05
332 NEURAL CREST CELL DIFFERENTIATION 4 75 1.53e-06 2.144e-05
333 NEGATIVE REGULATION OF MOLECULAR FUNCTION 9 1079 1.539e-06 2.151e-05
334 POSITIVE REGULATION OF NEUROBLAST PROLIFERATION 3 21 1.743e-06 2.421e-05
335 POSITIVE REGULATION OF ADHERENS JUNCTION ORGANIZATION 3 21 1.743e-06 2.421e-05
336 NEURON PROJECTION DEVELOPMENT 7 545 1.801e-06 2.494e-05
337 NEGATIVE REGULATION OF PROTEIN BINDING 4 79 1.886e-06 2.596e-05
338 CELL JUNCTION ORGANIZATION 5 185 1.886e-06 2.596e-05
339 REGULATION OF CELLULAR PROTEIN LOCALIZATION 7 552 1.961e-06 2.691e-05
340 CELLULAR RESPONSE TO MECHANICAL STIMULUS 4 80 1.983e-06 2.714e-05
341 REGULATION OF RESPONSE TO STRESS 10 1468 2.075e-06 2.832e-05
342 METANEPHROS DEVELOPMENT 4 81 2.085e-06 2.836e-05
343 NEGATIVE REGULATION OF NEURON DIFFERENTIATION 5 191 2.206e-06 2.992e-05
344 ORGAN REGENERATION 4 83 2.299e-06 3.11e-05
345 POSITIVE REGULATION OF ORGANELLE ORGANIZATION 7 573 2.512e-06 3.388e-05
346 CARDIAC SEPTUM DEVELOPMENT 4 85 2.529e-06 3.402e-05
347 RESPONSE TO ALCOHOL 6 362 2.625e-06 3.52e-05
348 NEGATIVE REGULATION OF STEROID METABOLIC PROCESS 3 24 2.647e-06 3.529e-05
349 POSITIVE REGULATION OF CELL JUNCTION ASSEMBLY 3 24 2.647e-06 3.529e-05
350 EPITHELIAL TUBE BRANCHING INVOLVED IN LUNG MORPHOGENESIS 3 25 3.005e-06 3.973e-05
351 REGULATION OF TRANSFORMING GROWTH FACTOR BETA PRODUCTION 3 25 3.005e-06 3.973e-05
352 POSITIVE REGULATION OF PEPTIDYL THREONINE PHOSPHORYLATION 3 25 3.005e-06 3.973e-05
353 AXIS SPECIFICATION 4 90 3.18e-06 4.168e-05
354 REGULATION OF CELL MATRIX ADHESION 4 90 3.18e-06 4.168e-05
355 REGULATION OF GLIOGENESIS 4 90 3.18e-06 4.168e-05
356 NEGATIVE REGULATION OF GLIAL CELL DIFFERENTIATION 3 26 3.395e-06 4.4e-05
357 NEGATIVE REGULATION OF EMBRYONIC DEVELOPMENT 3 26 3.395e-06 4.4e-05
358 HEART GROWTH 3 26 3.395e-06 4.4e-05
359 REGULATION OF HORMONE METABOLIC PROCESS 3 26 3.395e-06 4.4e-05
360 REGULATION OF ASTROCYTE DIFFERENTIATION 3 27 3.816e-06 4.905e-05
361 RESPONSE TO LITHIUM ION 3 27 3.816e-06 4.905e-05
362 POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER INVOLVED IN CELLULAR RESPONSE TO CHEMICAL STIMULUS 3 27 3.816e-06 4.905e-05
363 POSITIVE REGULATION OF TRANSFERASE ACTIVITY 7 616 4.053e-06 5.195e-05
364 REGULATION OF CELL GROWTH 6 391 4.093e-06 5.232e-05
365 RESPONSE TO ESTROGEN 5 218 4.214e-06 5.357e-05
366 REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS 5 218 4.214e-06 5.357e-05
367 REGULATION OF NEUROBLAST PROLIFERATION 3 28 4.271e-06 5.371e-05
368 DOPAMINERGIC NEURON DIFFERENTIATION 3 28 4.271e-06 5.371e-05
369 MAMMARY GLAND DUCT MORPHOGENESIS 3 28 4.271e-06 5.371e-05
370 METANEPHROS MORPHOGENESIS 3 28 4.271e-06 5.371e-05
371 REGULATION OF ENDOTHELIAL CELL PROLIFERATION 4 98 4.468e-06 5.604e-05
372 POSITIVE REGULATION OF CELL SUBSTRATE ADHESION 4 99 4.653e-06 5.82e-05
373 CELLULAR MACROMOLECULE LOCALIZATION 9 1234 4.67e-06 5.826e-05
374 NEGATIVE REGULATION OF CELL ADHESION 5 223 4.707e-06 5.856e-05
375 REGULATION OF CARDIAC MUSCLE CELL PROLIFERATION 3 29 4.76e-06 5.875e-05
376 REGULATION OF EXTRACELLULAR MATRIX ORGANIZATION 3 29 4.76e-06 5.875e-05
377 POSITIVE REGULATION OF CARTILAGE DEVELOPMENT 3 29 4.76e-06 5.875e-05
378 CELL PART MORPHOGENESIS 7 633 4.849e-06 5.953e-05
379 REGULATION OF SMOOTH MUSCLE CELL PROLIFERATION 4 100 4.843e-06 5.953e-05
380 REGULATION OF CELLULAR LOCALIZATION 9 1277 6.184e-06 7.573e-05
381 NEGATIVE REGULATION OF GROWTH 5 236 6.203e-06 7.576e-05
382 SALIVARY GLAND DEVELOPMENT 3 32 6.447e-06 7.853e-05
383 EMBRYONIC AXIS SPECIFICATION 3 33 7.087e-06 8.587e-05
384 REGULATION OF T CELL APOPTOTIC PROCESS 3 33 7.087e-06 8.587e-05
385 NEGATIVE REGULATION OF CELL CYCLE 6 433 7.346e-06 8.878e-05
386 EAR MORPHOGENESIS 4 112 7.601e-06 9.163e-05
387 POSITIVE REGULATION OF CELL CYCLE PROCESS 5 247 7.74e-06 9.306e-05
388 ORGAN FORMATION 3 34 7.767e-06 9.314e-05
389 NOTCH SIGNALING PATHWAY 4 114 8.154e-06 9.753e-05
390 NEURON DEVELOPMENT 7 687 8.296e-06 9.898e-05
391 RESPONSE TO FIBROBLAST GROWTH FACTOR 4 116 8.736e-06 0.000104
392 NEGATIVE REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION 4 117 9.039e-06 0.0001073
393 NEGATIVE REGULATION OF MUSCLE ORGAN DEVELOPMENT 3 36 9.253e-06 0.000109
394 NEGATIVE REGULATION OF MUSCLE TISSUE DEVELOPMENT 3 36 9.253e-06 0.000109
395 HEAD MORPHOGENESIS 3 36 9.253e-06 0.000109
396 NEGATIVE REGULATION OF GLIOGENESIS 3 37 1.006e-05 0.0001179
397 REGULATION OF PEPTIDYL THREONINE PHOSPHORYLATION 3 37 1.006e-05 0.0001179
398 CELL DIVISION 6 460 1.037e-05 0.0001213
399 CELLULAR RESPONSE TO ABIOTIC STIMULUS 5 263 1.049e-05 0.0001224
400 CELLULAR RESPONSE TO EXTERNAL STIMULUS 5 264 1.069e-05 0.000124
401 REGULATION OF EPITHELIAL CELL DIFFERENTIATION 4 122 1.067e-05 0.000124
402 TAXIS 6 464 1.09e-05 0.0001257
403 BONE MINERALIZATION 3 38 1.092e-05 0.0001257
404 POSITIVE REGULATION OF BIOMINERAL TISSUE DEVELOPMENT 3 38 1.092e-05 0.0001257
405 CELLULAR RESPONSE TO ORGANIC CYCLIC COMPOUND 6 465 1.103e-05 0.0001267
406 SEX DIFFERENTIATION 5 266 1.108e-05 0.000127
407 WOUND HEALING 6 470 1.172e-05 0.0001337
408 REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY 6 470 1.172e-05 0.0001337
409 REGULATION OF CELL DIVISION 5 272 1.235e-05 0.0001405
410 MAMMARY GLAND MORPHOGENESIS 3 40 1.277e-05 0.0001448
411 NEGATIVE REGULATION OF RESPONSE TO EXTERNAL STIMULUS 5 274 1.279e-05 0.0001448
412 MUSCLE ORGAN DEVELOPMENT 5 277 1.348e-05 0.0001523
413 POSITIVE REGULATION OF KINASE ACTIVITY 6 482 1.353e-05 0.0001524
414 POSITIVE REGULATION OF KIDNEY DEVELOPMENT 3 41 1.376e-05 0.0001547
415 POSITIVE REGULATION OF CELL DIVISION 4 132 1.456e-05 0.0001629
416 MAINTENANCE OF CELL NUMBER 4 132 1.456e-05 0.0001629
417 NEGATIVE REGULATION OF BMP SIGNALING PATHWAY 3 42 1.481e-05 0.0001645
418 POSITIVE REGULATION OF NEURAL PRECURSOR CELL PROLIFERATION 3 42 1.481e-05 0.0001645
419 REGULATION OF HEART GROWTH 3 42 1.481e-05 0.0001645
420 NEGATIVE REGULATION OF STEM CELL DIFFERENTIATION 3 43 1.591e-05 0.0001759
421 CELL GROWTH 4 135 1.591e-05 0.0001759
422 GLIAL CELL DIFFERENTIATION 4 136 1.638e-05 0.0001806
423 REGULATION OF DEVELOPMENTAL GROWTH 5 289 1.654e-05 0.000182
424 BODY MORPHOGENESIS 3 44 1.706e-05 0.0001868
425 NEGATIVE REGULATION OF LIPID BIOSYNTHETIC PROCESS 3 44 1.706e-05 0.0001868
426 REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING 4 138 1.735e-05 0.0001891
427 NEGATIVE REGULATION OF CELL CELL ADHESION 4 138 1.735e-05 0.0001891
428 VENTRICULAR CARDIAC MUSCLE TISSUE DEVELOPMENT 3 45 1.827e-05 0.0001981
429 REGULATION OF ALCOHOL BIOSYNTHETIC PROCESS 3 45 1.827e-05 0.0001981
430 EMBRYONIC CRANIAL SKELETON MORPHOGENESIS 3 46 1.953e-05 0.0002113
431 POSITIVE REGULATION OF CELL PROJECTION ORGANIZATION 5 303 2.077e-05 0.0002242
432 POSITIVE REGULATION OF NEURON APOPTOTIC PROCESS 3 47 2.084e-05 0.0002245
433 POSITIVE REGULATION OF NEURON DIFFERENTIATION 5 306 2.178e-05 0.000234
434 ANTERIOR POSTERIOR AXIS SPECIFICATION 3 48 2.221e-05 0.0002382
435 POSITIVE REGULATION OF CELL GROWTH 4 148 2.285e-05 0.0002444
436 NEURAL TUBE DEVELOPMENT 4 149 2.346e-05 0.0002504
437 REGULATION OF STEROID BIOSYNTHETIC PROCESS 3 49 2.365e-05 0.0002518
438 REGULATION OF ADHERENS JUNCTION ORGANIZATION 3 50 2.514e-05 0.0002664
439 ENDODERM FORMATION 3 50 2.514e-05 0.0002664
440 POSITIVE REGULATION OF WNT SIGNALING PATHWAY 4 152 2.537e-05 0.0002683
441 REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY 4 153 2.604e-05 0.0002741
442 PALLIUM DEVELOPMENT 4 153 2.604e-05 0.0002741
443 ARTERY MORPHOGENESIS 3 51 2.669e-05 0.0002803
444 CELLULAR RESPONSE TO INORGANIC SUBSTANCE 4 156 2.81e-05 0.0002938
445 PROTEIN LOCALIZATION TO NUCLEUS 4 156 2.81e-05 0.0002938
446 PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS 10 1977 2.971e-05 0.00031
447 PROTEIN LOCALIZATION TO ORGANELLE 6 556 3.03e-05 0.0003154
448 IMMUNE SYSTEM PROCESS 10 1984 3.065e-05 0.0003183
449 NEGATIVE REGULATION OF REPRODUCTIVE PROCESS 3 54 3.171e-05 0.0003279
450 REGULATION OF LYMPHOCYTE APOPTOTIC PROCESS 3 54 3.171e-05 0.0003279
451 REGENERATION 4 161 3.179e-05 0.000328
452 RESPONSE TO WOUNDING 6 563 3.25e-05 0.0003346
453 RESPONSE TO METAL ION 5 333 3.265e-05 0.0003354
454 NEGATIVE REGULATION OF MUSCLE CELL DIFFERENTIATION 3 55 3.352e-05 0.0003428
455 CRANIAL SKELETAL SYSTEM DEVELOPMENT 3 55 3.352e-05 0.0003428
456 SMAD PROTEIN SIGNAL TRANSDUCTION 3 56 3.539e-05 0.0003603
457 POSITIVE REGULATION OF MUSCLE TISSUE DEVELOPMENT 3 56 3.539e-05 0.0003603
458 POSITIVE REGULATION OF EPITHELIAL CELL DIFFERENTIATION 3 57 3.733e-05 0.0003792
459 POSITIVE REGULATION OF DNA BIOSYNTHETIC PROCESS 3 59 4.141e-05 0.0004198
460 POSITIVE REGULATION OF SMOOTH MUSCLE CELL PROLIFERATION 3 60 4.356e-05 0.0004396
461 CHONDROCYTE DIFFERENTIATION 3 60 4.356e-05 0.0004396
462 CELLULAR RESPONSE TO ACID CHEMICAL 4 175 4.404e-05 0.0004435
463 REGULATION OF VIRAL TRANSCRIPTION 3 61 4.578e-05 0.00046
464 SOMITOGENESIS 3 62 4.807e-05 0.0004798
465 CELL PROJECTION ORGANIZATION 7 902 4.816e-05 0.0004798
466 POSITIVE REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING 3 62 4.807e-05 0.0004798
467 EMBRYONIC HEART TUBE MORPHOGENESIS 3 62 4.807e-05 0.0004798
468 POSITIVE REGULATION OF HYDROLASE ACTIVITY 7 905 4.919e-05 0.000489
469 REGULATION OF PROTEIN IMPORT 4 183 5.242e-05 0.0005201
470 NEGATIVE REGULATION OF PROTEIN MODIFICATION PROCESS 6 616 5.374e-05 0.0005321
471 POSITIVE REGULATION OF CYTOKINE PRODUCTION 5 370 5.393e-05 0.0005328
472 CELLULAR RESPONSE TO RETINOIC ACID 3 65 5.539e-05 0.0005437
473 REGULATION OF CHEMOKINE PRODUCTION 3 65 5.539e-05 0.0005437
474 REGULATION OF RESPONSE TO OXIDATIVE STRESS 3 65 5.539e-05 0.0005437
475 FOREBRAIN GENERATION OF NEURONS 3 66 5.798e-05 0.0005668
476 LENS DEVELOPMENT IN CAMERA TYPE EYE 3 66 5.798e-05 0.0005668
477 POSITIVE REGULATION OF NEURON DEATH 3 67 6.066e-05 0.0005904
478 NEURON FATE COMMITMENT 3 67 6.066e-05 0.0005904
479 REGULATION OF NEURON APOPTOTIC PROCESS 4 192 6.318e-05 0.0006138
480 DEVELOPMENTAL MATURATION 4 193 6.447e-05 0.000625
481 RESPONSE TO ACTIVITY 3 69 6.624e-05 0.0006408
482 POSITIVE REGULATION OF HORMONE METABOLIC PROCESS 2 11 6.914e-05 0.0006593
483 REGULATION OF EXTRACELLULAR MATRIX ASSEMBLY 2 11 6.914e-05 0.0006593
484 NEGATIVE REGULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR SIGNALING PATHWAY 2 11 6.914e-05 0.0006593
485 RESPONSE TO FOLLICLE STIMULATING HORMONE 2 11 6.914e-05 0.0006593
486 PROSTATE GLAND GROWTH 2 11 6.914e-05 0.0006593
487 EPITHELIAL TO MESENCHYMAL TRANSITION INVOLVED IN ENDOCARDIAL CUSHION FORMATION 2 11 6.914e-05 0.0006593
488 PROSTATE GLANDULAR ACINUS DEVELOPMENT 2 11 6.914e-05 0.0006593
489 REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE 4 197 6.982e-05 0.0006643
490 NEGATIVE REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT 3 71 7.215e-05 0.0006838
491 CELL FATE SPECIFICATION 3 71 7.215e-05 0.0006838
492 PANCREAS DEVELOPMENT 3 73 7.84e-05 0.0007399
493 REGULATION OF ORGAN GROWTH 3 73 7.84e-05 0.0007399
494 RESPONSE TO PEPTIDE 5 404 8.177e-05 0.0007655
495 REGULATION OF STEROID METABOLIC PROCESS 3 74 8.165e-05 0.0007655
496 NEURON PROJECTION GUIDANCE 4 205 8.147e-05 0.0007655
497 SIGNAL TRANSDUCTION BY PROTEIN PHOSPHORYLATION 5 404 8.177e-05 0.0007655
498 REGULATION OF THYMOCYTE APOPTOTIC PROCESS 2 12 8.291e-05 0.00077
499 REGULATION OF MACROPHAGE CYTOKINE PRODUCTION 2 12 8.291e-05 0.00077
500 POSITIVE REGULATION OF ASTROCYTE DIFFERENTIATION 2 12 8.291e-05 0.00077
501 NEGATIVE REGULATION OF RECEPTOR BINDING 2 12 8.291e-05 0.00077
502 ARTERY DEVELOPMENT 3 75 8.499e-05 0.0007862
503 BIOMINERAL TISSUE DEVELOPMENT 3 75 8.499e-05 0.0007862
504 REGULATION OF GTPASE ACTIVITY 6 673 8.779e-05 0.0008105
505 RESPONSE TO MECHANICAL STIMULUS 4 210 8.943e-05 0.000824
506 NEGATIVE REGULATION OF CYTOKINE PRODUCTION 4 211 9.109e-05 0.0008377
507 REGULATION OF BMP SIGNALING PATHWAY 3 77 9.193e-05 0.0008437
508 CELL DEATH 7 1001 9.316e-05 0.0008533
509 NEGATIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION 6 684 9.601e-05 0.0008777
510 NEURONAL STEM CELL DIVISION 2 13 9.792e-05 0.0008796
511 NEGATIVE REGULATION OF OLIGODENDROCYTE DIFFERENTIATION 2 13 9.792e-05 0.0008796
512 LEFT RIGHT AXIS SPECIFICATION 2 13 9.792e-05 0.0008796
513 CELLULAR RESPONSE TO HEPATOCYTE GROWTH FACTOR STIMULUS 2 13 9.792e-05 0.0008796
514 HEART VALVE FORMATION 2 13 9.792e-05 0.0008796
515 CARDIOBLAST DIFFERENTIATION 2 13 9.792e-05 0.0008796
516 RESPONSE TO HEPATOCYTE GROWTH FACTOR 2 13 9.792e-05 0.0008796
517 NEUROBLAST DIVISION 2 13 9.792e-05 0.0008796
518 GLIAL CELL FATE COMMITMENT 2 13 9.792e-05 0.0008796
519 REGULATION OF TRANSPORT 9 1804 9.819e-05 0.0008803
520 REGULATION OF LEUKOCYTE APOPTOTIC PROCESS 3 79 9.923e-05 0.0008879
521 DEVELOPMENT OF PRIMARY SEXUAL CHARACTERISTICS 4 216 9.972e-05 0.0008906
522 NEGATIVE REGULATION OF LIPID METABOLIC PROCESS 3 80 0.000103 0.0009165
523 NEGATIVE REGULATION OF VASCULATURE DEVELOPMENT 3 80 0.000103 0.0009165
524 REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT 4 220 0.000107 0.0009506
525 CELL MIGRATION INVOLVED IN HEART DEVELOPMENT 2 14 0.0001142 0.0009966
526 RENAL VESICLE DEVELOPMENT 2 14 0.0001142 0.0009966
527 POSITIVE REGULATION OF MEIOTIC CELL CYCLE 2 14 0.0001142 0.0009966
528 REGULATION OF GLOMERULUS DEVELOPMENT 2 14 0.0001142 0.0009966
529 METANEPHRIC MESENCHYME DEVELOPMENT 2 14 0.0001142 0.0009966
530 REGULATION OF PROTEIN KINASE C SIGNALING 2 14 0.0001142 0.0009966
531 CONVERGENT EXTENSION 2 14 0.0001142 0.0009966
532 ADENOHYPOPHYSIS DEVELOPMENT 2 14 0.0001142 0.0009966
533 MIDGUT DEVELOPMENT 2 14 0.0001142 0.0009966
534 EMBRYONIC PLACENTA DEVELOPMENT 3 83 0.000115 0.001002
535 NEGATIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 5 437 0.0001183 0.001029
536 RESPONSE TO CYTOKINE 6 714 0.0001216 0.001055
537 POSITIVE REGULATION OF ENDOTHELIAL CELL DIFFERENTIATION 2 15 0.0001316 0.001132
538 OTIC VESICLE DEVELOPMENT 2 15 0.0001316 0.001132
539 ENDOCARDIAL CUSHION FORMATION 2 15 0.0001316 0.001132
540 POSITIVE REGULATION OF T CELL APOPTOTIC PROCESS 2 15 0.0001316 0.001132
541 POSITIVE REGULATION OF NEURON PROJECTION DEVELOPMENT 4 232 0.0001314 0.001132
542 TISSUE REMODELING 3 87 0.0001322 0.001135
543 REGULATION OF CATABOLIC PROCESS 6 731 0.0001383 0.001185
544 SEGMENTATION 3 89 0.0001414 0.001208
545 EPITHELIAL CELL PROLIFERATION 3 89 0.0001414 0.001208
546 MIDBRAIN DEVELOPMENT 3 90 0.0001462 0.001246
547 SINGLE ORGANISM CELL ADHESION 5 459 0.0001489 0.001267
548 MORPHOGENESIS OF AN ENDOTHELIUM 2 16 0.0001503 0.001267
549 ORGAN INDUCTION 2 16 0.0001503 0.001267
550 APOPTOTIC PROCESS INVOLVED IN MORPHOGENESIS 2 16 0.0001503 0.001267
551 ATRIOVENTRICULAR VALVE MORPHOGENESIS 2 16 0.0001503 0.001267
552 BRANCHING INVOLVED IN SALIVARY GLAND MORPHOGENESIS 2 16 0.0001503 0.001267
553 CELL CYCLE PROCESS 7 1081 0.0001508 0.001269
554 NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS 7 1087 0.0001561 0.001309
555 INNER EAR MORPHOGENESIS 3 92 0.0001561 0.001309
556 REGULATION OF DNA BINDING 3 93 0.0001611 0.001348
557 REGULATION OF DNA BIOSYNTHETIC PROCESS 3 94 0.0001663 0.001387
558 NEURAL TUBE FORMATION 3 94 0.0001663 0.001387
559 NEGATIVE REGULATION OF KIDNEY DEVELOPMENT 2 17 0.0001703 0.001402
560 CELLULAR RESPONSE TO LITHIUM ION 2 17 0.0001703 0.001402
561 REGULATION OF RECEPTOR BINDING 2 17 0.0001703 0.001402
562 POSITIVE REGULATION OF EXTRACELLULAR MATRIX ORGANIZATION 2 17 0.0001703 0.001402
563 NEGATIVE REGULATION OF ANOIKIS 2 17 0.0001703 0.001402
564 REGULATION OF STEM CELL POPULATION MAINTENANCE 2 17 0.0001703 0.001402
565 NEGATIVE REGULATION OF CARDIAC MUSCLE TISSUE DEVELOPMENT 2 17 0.0001703 0.001402
566 NEGATIVE REGULATION OF INTRACELLULAR PROTEIN TRANSPORT 3 95 0.0001716 0.001408
567 TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY 3 95 0.0001716 0.001408
568 CARDIOCYTE DIFFERENTIATION 3 96 0.000177 0.00145
569 REGULATION OF NEURON DEATH 4 252 0.0001805 0.001476
570 RESPONSE TO INORGANIC SUBSTANCE 5 479 0.0001817 0.001483
571 NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY 3 98 0.0001882 0.001533
572 LEUKOCYTE CELL CELL ADHESION 4 255 0.0001888 0.001536
573 KIDNEY MESENCHYME DEVELOPMENT 2 18 0.0001914 0.001554
574 LIMBIC SYSTEM DEVELOPMENT 3 100 0.0001997 0.001619
575 POSITIVE REGULATION OF CARDIAC MUSCLE CELL PROLIFERATION 2 19 0.0002138 0.001727
576 ATRIOVENTRICULAR VALVE DEVELOPMENT 2 19 0.0002138 0.001727
577 CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND 6 799 0.0002246 0.001811
578 CEREBRAL CORTEX DEVELOPMENT 3 105 0.0002307 0.001857
579 POSITIVE REGULATION OF LYMPHOCYTE APOPTOTIC PROCESS 2 20 0.0002374 0.001888
580 REGULATION OF FAT CELL DIFFERENTIATION 3 106 0.0002372 0.001888
581 NEGATIVE REGULATION OF BIOMINERAL TISSUE DEVELOPMENT 2 20 0.0002374 0.001888
582 METANEPHRIC EPITHELIUM DEVELOPMENT 2 20 0.0002374 0.001888
583 TONGUE DEVELOPMENT 2 20 0.0002374 0.001888
584 FAT CELL DIFFERENTIATION 3 106 0.0002372 0.001888
585 BRANCHING INVOLVED IN MAMMARY GLAND DUCT MORPHOGENESIS 2 20 0.0002374 0.001888
586 RESPONSE TO RETINOIC ACID 3 107 0.0002439 0.001937
587 POSITIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION 5 514 0.0002521 0.001999
588 METANEPHRIC NEPHRON MORPHOGENESIS 2 21 0.0002622 0.002054
589 LEFT RIGHT PATTERN FORMATION 2 21 0.0002622 0.002054
590 ECTODERM DEVELOPMENT 2 21 0.0002622 0.002054
591 CELL AGGREGATION 2 21 0.0002622 0.002054
592 APOPTOTIC PROCESS INVOLVED IN DEVELOPMENT 2 21 0.0002622 0.002054
593 COCHLEA MORPHOGENESIS 2 21 0.0002622 0.002054
594 CARTILAGE CONDENSATION 2 21 0.0002622 0.002054
595 NEGATIVE REGULATION OF CATALYTIC ACTIVITY 6 829 0.0002742 0.002144
596 SEX DETERMINATION 2 22 0.0002882 0.002231
597 BETA CATENIN DESTRUCTION COMPLEX DISASSEMBLY 2 22 0.0002882 0.002231
598 MODULATION OF TRANSCRIPTION IN OTHER ORGANISM INVOLVED IN SYMBIOTIC INTERACTION 2 22 0.0002882 0.002231
599 PROTEIN LOCALIZATION TO CELL SURFACE 2 22 0.0002882 0.002231
600 EMBRYONIC PLACENTA MORPHOGENESIS 2 22 0.0002882 0.002231
601 POSITIVE REGULATION OF MESONEPHROS DEVELOPMENT 2 22 0.0002882 0.002231
602 POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER IN RESPONSE TO STRESS 2 23 0.0003154 0.00243
603 REGULATION OF OSTEOBLAST PROLIFERATION 2 23 0.0003154 0.00243
604 ADRENAL GLAND DEVELOPMENT 2 23 0.0003154 0.00243
605 NEGATIVE REGULATION OF CYTOPLASMIC TRANSPORT 3 117 0.0003173 0.002436
606 SPECIFICATION OF SYMMETRY 3 117 0.0003173 0.002436
607 NEGATIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS 5 541 0.0003194 0.002444
608 NEGATIVE REGULATION OF PHOSPHATE METABOLIC PROCESS 5 541 0.0003194 0.002444
609 REGULATION OF PEPTIDYL SERINE PHOSPHORYLATION 3 118 0.0003253 0.002485
610 RESPONSE TO NITROGEN COMPOUND 6 859 0.0003321 0.002533
611 CYTOKINE PRODUCTION 3 120 0.0003417 0.002602
612 EMBRYONIC CAMERA TYPE EYE MORPHOGENESIS 2 24 0.0003438 0.002606
613 NEGATIVE REGULATION OF MYOBLAST DIFFERENTIATION 2 24 0.0003438 0.002606
614 REGULATION OF ANOIKIS 2 24 0.0003438 0.002606
615 CELLULAR RESPONSE TO HORMONE STIMULUS 5 552 0.0003504 0.002651
616 T CELL DIFFERENTIATION 3 123 0.0003674 0.002775
617 REGULATION OF CELL PROJECTION ORGANIZATION 5 558 0.0003683 0.002777
618 CELLULAR RESPONSE TO EPIDERMAL GROWTH FACTOR STIMULUS 2 25 0.0003735 0.002807
619 LUNG CELL DIFFERENTIATION 2 25 0.0003735 0.002807
620 REGULATION OF PROTEIN TARGETING 4 307 0.0003828 0.002873
621 STEROID HORMONE MEDIATED SIGNALING PATHWAY 3 125 0.0003852 0.002886
622 DEVELOPMENTAL PROGRAMMED CELL DEATH 2 26 0.0004043 0.002996
623 NEGATIVE REGULATION OF STRIATED MUSCLE CELL DIFFERENTIATION 2 26 0.0004043 0.002996
624 HEART TRABECULA MORPHOGENESIS 2 26 0.0004043 0.002996
625 REGULATION OF MESONEPHROS DEVELOPMENT 2 26 0.0004043 0.002996
626 MESODERMAL CELL DIFFERENTIATION 2 26 0.0004043 0.002996
627 MULTI ORGANISM REPRODUCTIVE PROCESS 6 891 0.0004041 0.002996
628 REGULATION OF P38MAPK CASCADE 2 26 0.0004043 0.002996
629 REGULATION OF LIPID BIOSYNTHETIC PROCESS 3 128 0.0004129 0.003055
630 REGULATION OF HEMOPOIESIS 4 314 0.0004169 0.003079
631 CELL JUNCTION ASSEMBLY 3 129 0.0004224 0.003115
632 REGULATION OF ENDOTHELIAL CELL DIFFERENTIATION 2 27 0.0004363 0.003202
633 POSITIVE REGULATION OF HEART GROWTH 2 27 0.0004363 0.003202
634 SUBSTRATE DEPENDENT CELL MIGRATION 2 27 0.0004363 0.003202
635 POSITIVE REGULATION OF VASCULATURE DEVELOPMENT 3 133 0.0004619 0.003385
636 POSITIVE REGULATION OF LEUKOCYTE APOPTOTIC PROCESS 2 28 0.0004696 0.003425
637 GASTRULATION WITH MOUTH FORMING SECOND 2 28 0.0004696 0.003425
638 RESPONSE TO GONADOTROPIN 2 28 0.0004696 0.003425
639 NEGATIVE REGULATION OF CELLULAR PROTEIN LOCALIZATION 3 135 0.0004825 0.003508
640 POSITIVE REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE 3 135 0.0004825 0.003508
641 GAMETE GENERATION 5 595 0.0004941 0.003587
642 REGULATION OF RESPONSE TO EXTERNAL STIMULUS 6 926 0.0004964 0.003598
643 HINDBRAIN DEVELOPMENT 3 137 0.0005037 0.003613
644 REGULATION OF MEIOTIC NUCLEAR DIVISION 2 29 0.000504 0.003613
645 EMBRYONIC HINDLIMB MORPHOGENESIS 2 29 0.000504 0.003613
646 POSITIVE REGULATION OF CARDIAC MUSCLE TISSUE DEVELOPMENT 2 29 0.000504 0.003613
647 REGULATION OF OLIGODENDROCYTE DIFFERENTIATION 2 29 0.000504 0.003613
648 NEUROBLAST PROLIFERATION 2 29 0.000504 0.003613
649 ACTIVATION OF MAPK ACTIVITY 3 137 0.0005037 0.003613
650 CELL CYCLE 7 1316 0.0005054 0.003618
651 PLACENTA DEVELOPMENT 3 138 0.0005145 0.003677
652 PROTEIN LOCALIZATION TO CYTOSKELETON 2 30 0.0005396 0.003828
653 ESTABLISHMENT OR MAINTENANCE OF EPITHELIAL CELL APICAL BASAL POLARITY 2 30 0.0005396 0.003828
654 RESPONSE TO EPIDERMAL GROWTH FACTOR 2 30 0.0005396 0.003828
655 NEGATIVE REGULATION OF MUSCLE CELL APOPTOTIC PROCESS 2 30 0.0005396 0.003828
656 CELLULAR RESPONSE TO CYTOKINE STIMULUS 5 606 0.0005372 0.003828
657 CELL CELL ADHESION 5 608 0.0005453 0.003862
658 ESTABLISHMENT OR MAINTENANCE OF CELL POLARITY 3 141 0.0005478 0.003874
659 EPIDERMAL CELL DIFFERENTIATION 3 142 0.0005592 0.003948
660 REGULATION OF DNA METABOLIC PROCESS 4 340 0.0005627 0.003967
661 CELLULAR RESPONSE TO OXYGEN LEVELS 3 143 0.0005708 0.004012
662 NEGATIVE REGULATION OF INTRACELLULAR TRANSPORT 3 143 0.0005708 0.004012
663 CARDIAC ATRIUM DEVELOPMENT 2 31 0.0005764 0.004045
664 POSITIVE REGULATION OF GLIAL CELL DIFFERENTIATION 2 32 0.0006144 0.00428
665 PATTERNING OF BLOOD VESSELS 2 32 0.0006144 0.00428
666 REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER IN RESPONSE TO HYPOXIA 2 32 0.0006144 0.00428
667 POSITIVE REGULATION OF EPIDERMIS DEVELOPMENT 2 32 0.0006144 0.00428
668 METANEPHRIC NEPHRON DEVELOPMENT 2 32 0.0006144 0.00428
669 PEPTIDYL SERINE MODIFICATION 3 148 0.0006308 0.004387
670 REGULATION OF MYELINATION 2 33 0.0006536 0.004512
671 EMBRYONIC DIGESTIVE TRACT DEVELOPMENT 2 33 0.0006536 0.004512
672 POSITIVE REGULATION OF RESPONSE TO CYTOKINE STIMULUS 2 33 0.0006536 0.004512
673 EMBRYONIC EYE MORPHOGENESIS 2 33 0.0006536 0.004512
674 POSITIVE REGULATION OF EMBRYONIC DEVELOPMENT 2 33 0.0006536 0.004512
675 CHROMATIN REMODELING 3 150 0.0006559 0.004522
676 FOREBRAIN NEURON DEVELOPMENT 2 34 0.000694 0.004777
677 NEGATIVE REGULATION OF RESPONSE TO OXIDATIVE STRESS 2 35 0.0007355 0.005011
678 BONE DEVELOPMENT 3 156 0.0007351 0.005011
679 POSITIVE REGULATION OF DEVELOPMENTAL GROWTH 3 156 0.0007351 0.005011
680 HAIR CELL DIFFERENTIATION 2 35 0.0007355 0.005011
681 NEGATIVE REGULATION OF CELLULAR RESPONSE TO OXIDATIVE STRESS 2 35 0.0007355 0.005011
682 EMBRYONIC CAMERA TYPE EYE DEVELOPMENT 2 35 0.0007355 0.005011
683 REGULATION OF RESPONSE TO REACTIVE OXYGEN SPECIES 2 35 0.0007355 0.005011
684 REGULATION OF IMMUNE SYSTEM PROCESS 7 1403 0.0007431 0.005055
685 HORMONE MEDIATED SIGNALING PATHWAY 3 158 0.0007628 0.005181
686 CELL DIFFERENTIATION INVOLVED IN KIDNEY DEVELOPMENT 2 36 0.0007783 0.005263
687 REGULATION OF TRANSCRIPTION REGULATORY REGION DNA BINDING 2 36 0.0007783 0.005263
688 POSITIVE CHEMOTAXIS 2 36 0.0007783 0.005263
689 NEGATIVE REGULATION OF IMMUNE SYSTEM PROCESS 4 372 0.0007882 0.005323
690 CELL CHEMOTAXIS 3 162 0.0008201 0.005504
691 HINDLIMB MORPHOGENESIS 2 37 0.0008221 0.005504
692 MYOBLAST DIFFERENTIATION 2 37 0.0008221 0.005504
693 GLIAL CELL MIGRATION 2 37 0.0008221 0.005504
694 ESTABLISHMENT OR MAINTENANCE OF APICAL BASAL CELL POLARITY 2 37 0.0008221 0.005504
695 ESTABLISHMENT OR MAINTENANCE OF BIPOLAR CELL POLARITY 2 37 0.0008221 0.005504
696 REGULATION OF NUCLEAR DIVISION 3 163 0.0008349 0.005573
697 CELLULAR RESPONSE TO BIOTIC STIMULUS 3 163 0.0008349 0.005573
698 REGULATION OF INTRACELLULAR PROTEIN TRANSPORT 4 381 0.0008616 0.005744
699 COLLAGEN FIBRIL ORGANIZATION 2 38 0.0008672 0.005756
700 OOCYTE DIFFERENTIATION 2 38 0.0008672 0.005756
701 POSITIVE REGULATION OF ORGAN GROWTH 2 38 0.0008672 0.005756
702 CENTRAL NERVOUS SYSTEM NEURON DIFFERENTIATION 3 166 0.0008801 0.005826
703 BIOLOGICAL ADHESION 6 1032 0.00088 0.005826
704 POSITIVE REGULATION OF VIRAL TRANSCRIPTION 2 39 0.0009135 0.005986
705 NEGATIVE REGULATION OF TRANSCRIPTION FACTOR IMPORT INTO NUCLEUS 2 39 0.0009135 0.005986
706 ANATOMICAL STRUCTURE MATURATION 2 39 0.0009135 0.005986
707 TRABECULA MORPHOGENESIS 2 39 0.0009135 0.005986
708 REGULATION OF CELL ADHESION MEDIATED BY INTEGRIN 2 39 0.0009135 0.005986
709 ASTROCYTE DIFFERENTIATION 2 39 0.0009135 0.005986
710 COCHLEA DEVELOPMENT 2 39 0.0009135 0.005986
711 NEGATIVE REGULATION OF CELL GROWTH 3 170 0.0009429 0.006171
712 REGULATION OF MEIOTIC CELL CYCLE 2 40 0.0009609 0.006244
713 ENDOCRINE PANCREAS DEVELOPMENT 2 40 0.0009609 0.006244
714 ENDODERMAL CELL DIFFERENTIATION 2 40 0.0009609 0.006244
715 NEGATIVE REGULATION OF OSTEOBLAST DIFFERENTIATION 2 40 0.0009609 0.006244
716 POSITIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY 3 171 0.000959 0.006244
717 REGULATION OF PROTEIN CATABOLIC PROCESS 4 393 0.000967 0.006275
718 REGULATION OF CELL SIZE 3 172 0.0009753 0.00632
719 POSITIVE REGULATION OF CATABOLIC PROCESS 4 395 0.0009854 0.006377
720 STRIATED MUSCLE CELL DIFFERENTIATION 3 173 0.0009918 0.006409
721 LUNG ALVEOLUS DEVELOPMENT 2 41 0.001009 0.006514
722 HOMEOSTASIS OF NUMBER OF CELLS 3 175 0.001025 0.006607
723 RESPONSE TO CORTICOSTEROID 3 176 0.001042 0.006708
724 EPITHELIAL CELL MORPHOGENESIS 2 42 0.001059 0.006798
725 GENITALIA DEVELOPMENT 2 42 0.001059 0.006798
726 REGULATION OF MUSCLE CELL APOPTOTIC PROCESS 2 43 0.00111 0.007092
727 MORPHOGENESIS OF AN EPITHELIAL SHEET 2 43 0.00111 0.007092
728 REGULATION OF NEURON PROJECTION DEVELOPMENT 4 408 0.001111 0.007092
729 BETA CATENIN TCF COMPLEX ASSEMBLY 2 43 0.00111 0.007092
730 RESPONSE TO KETONE 3 182 0.001148 0.007317
731 LABYRINTHINE LAYER DEVELOPMENT 2 44 0.001162 0.007397
732 REGULATION OF MYELOID CELL DIFFERENTIATION 3 183 0.001166 0.007413
733 TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 5 724 0.001199 0.007609
734 POSITIVE REGULATION OF DNA METABOLIC PROCESS 3 185 0.001203 0.007628
735 THYMOCYTE AGGREGATION 2 45 0.001215 0.007673
736 SPROUTING ANGIOGENESIS 2 45 0.001215 0.007673
737 T CELL DIFFERENTIATION IN THYMUS 2 45 0.001215 0.007673
738 PROTEIN COMPLEX SUBUNIT ORGANIZATION 7 1527 0.001229 0.007748
739 SEXUAL REPRODUCTION 5 730 0.001244 0.00783
740 NEGATIVE REGULATION OF PHOSPHORYLATION 4 422 0.001259 0.007915
741 NEGATIVE REGULATION OF DNA BINDING 2 46 0.00127 0.00794
742 PEPTIDYL THREONINE MODIFICATION 2 46 0.00127 0.00794
743 REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND 2 46 0.00127 0.00794
744 REGULATION OF OXIDATIVE STRESS INDUCED CELL DEATH 2 46 0.00127 0.00794
745 MYELOID CELL DIFFERENTIATION 3 189 0.00128 0.007992
746 THYMUS DEVELOPMENT 2 47 0.001325 0.008254
747 POSITIVE REGULATION OF GLIOGENESIS 2 47 0.001325 0.008254
748 RESPONSE TO DRUG 4 431 0.001361 0.008464
749 REGULATION OF MYOBLAST DIFFERENTIATION 2 48 0.001382 0.008561
750 COLUMNAR CUBOIDAL EPITHELIAL CELL DEVELOPMENT 2 48 0.001382 0.008561
751 POSITIVE REGULATION OF ACTIN FILAMENT BUNDLE ASSEMBLY 2 48 0.001382 0.008561
752 CELLULAR RESPONSE TO STRESS 7 1565 0.00142 0.008786
753 REGULATION OF NITRIC OXIDE SYNTHASE ACTIVITY 2 49 0.00144 0.008884
754 POSITIVE REGULATION OF CHEMOKINE PRODUCTION 2 49 0.00144 0.008884
755 NEGATIVE REGULATION OF MITOTIC CELL CYCLE 3 199 0.001484 0.009144
756 POSITIVE REGULATION OF FAT CELL DIFFERENTIATION 2 51 0.001559 0.009568
757 NEURAL CREST CELL MIGRATION 2 51 0.001559 0.009568
758 NEGATIVE REGULATION OF CHEMOTAXIS 2 51 0.001559 0.009568
759 REGULATION OF SYMBIOSIS ENCOMPASSING MUTUALISM THROUGH PARASITISM 3 205 0.001616 0.009904
760 NEGATIVE REGULATION OF RESPONSE TO DNA DAMAGE STIMULUS 2 52 0.00162 0.009904
761 INTERACTION WITH SYMBIONT 2 52 0.00162 0.009904
NumGOOverlapSizeP ValueAdj. P Value
1 RECEPTOR BINDING 14 1476 5.81e-11 5.397e-08
2 TRANSFORMING GROWTH FACTOR BETA RECEPTOR BINDING 5 50 2.586e-09 1.201e-06
3 SMAD BINDING 5 72 1.68e-08 5.201e-06
4 MACROMOLECULAR COMPLEX BINDING 11 1399 1.164e-07 2.703e-05
5 TRANSCRIPTION FACTOR ACTIVITY RNA POLYMERASE II DISTAL ENHANCER SEQUENCE SPECIFIC BINDING 4 90 3.18e-06 0.0005908
6 PROTEIN KINASE ACTIVITY 7 640 5.213e-06 0.0008071
7 CHROMATIN BINDING 6 435 7.542e-06 0.001001
8 FRIZZLED BINDING 3 36 9.253e-06 0.001075
9 PROTEIN HETERODIMERIZATION ACTIVITY 6 468 1.144e-05 0.001127
10 CYTOKINE RECEPTOR BINDING 5 271 1.213e-05 0.001127
11 PROTEIN DIMERIZATION ACTIVITY 8 1149 2.613e-05 0.001801
12 REGULATORY REGION NUCLEIC ACID BINDING 7 818 2.575e-05 0.001801
13 KINASE ACTIVITY 7 842 3.101e-05 0.001801
14 GROWTH FACTOR ACTIVITY 4 160 3.103e-05 0.001801
15 TRANSCRIPTION FACTOR ACTIVITY RNA POLYMERASE II CORE PROMOTER PROXIMAL REGION SEQUENCE SPECIFIC BINDING 5 328 3.037e-05 0.001801
16 TRANSCRIPTION FACTOR BINDING 6 524 2.17e-05 0.001801
17 NUCLEIC ACID BINDING TRANSCRIPTION FACTOR ACTIVITY 8 1199 3.553e-05 0.001941
18 KINASE BINDING 6 606 4.906e-05 0.002532
19 PROTEIN COMPLEX BINDING 7 935 6.052e-05 0.002959
20 I SMAD BINDING 2 11 6.914e-05 0.003212
21 TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS 7 992 8.8e-05 0.003893
22 BETA CATENIN BINDING 3 84 0.0001191 0.004217
23 TRANSMEMBRANE RECEPTOR PROTEIN KINASE ACTIVITY 3 81 0.0001069 0.004217
24 C2H2 ZINC FINGER DOMAIN BINDING 2 14 0.0001142 0.004217
25 RECEPTOR SERINE THREONINE KINASE BINDING 2 15 0.0001316 0.004217
26 PROTEIN KINASE A CATALYTIC SUBUNIT BINDING 2 15 0.0001316 0.004217
27 TRANSCRIPTIONAL ACTIVATOR ACTIVITY RNA POLYMERASE II CORE PROMOTER PROXIMAL REGION SEQUENCE SPECIFIC BINDING 4 226 0.0001188 0.004217
28 PROTEIN SERINE THREONINE KINASE ACTIVITY 5 445 0.0001288 0.004217
29 CYTOKINE ACTIVITY 4 219 0.0001052 0.004217
30 TRANSFORMING GROWTH FACTOR BETA BINDING 2 16 0.0001503 0.004505
31 RECEPTOR AGONIST ACTIVITY 2 16 0.0001503 0.004505
32 CYTOKINE BINDING 3 92 0.0001561 0.00453
33 TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE ACTIVITY 2 17 0.0001703 0.004793
34 DNA BINDING BENDING 2 20 0.0002374 0.006485
35 IONOTROPIC GLUTAMATE RECEPTOR BINDING 2 23 0.0003154 0.008139
36 FIBROBLAST GROWTH FACTOR BINDING 2 23 0.0003154 0.008139
37 GROWTH FACTOR BINDING 3 123 0.0003674 0.009225
NumGOOverlapSizeP ValueAdj. P Value
1 EXTRACELLULAR MATRIX 7 426 3.457e-07 0.0002019
2 EXTRACELLULAR SPACE 10 1376 1.149e-06 0.0003354
3 CELL SURFACE 7 757 1.561e-05 0.002278
4 NUCLEAR TRANSCRIPTION FACTOR COMPLEX 4 127 1.25e-05 0.002278
5 WNT SIGNALOSOME 2 11 6.914e-05 0.008076

Over-represented Pathway

NumPathwayPathviewOverlapSizeP ValueAdj. P Value
1 hsa04390_Hippo_signaling_pathway 11 154 4.904e-18 8.827e-16
2 hsa04340_Hedgehog_signaling_pathway 6 56 3.558e-11 3.202e-09
3 hsa04916_Melanogenesis 6 101 1.344e-09 8.063e-08
4 hsa04310_Wnt_signaling_pathway 6 151 1.522e-08 6.849e-07
5 hsa04350_TGF.beta_signaling_pathway 5 85 3.9e-08 1.404e-06
6 hsa04520_Adherens_junction 4 73 1.372e-06 4.117e-05
7 hsa04510_Focal_adhesion 3 200 0.001505 0.03534
8 hsa04144_Endocytosis 3 203 0.001571 0.03534
9 hsa04010_MAPK_signaling_pathway 3 268 0.003455 0.06911
10 hsa04151_PI3K_AKT_signaling_pathway 3 351 0.007315 0.1317
11 hsa04110_Cell_cycle 2 128 0.009417 0.1412
12 hsa04380_Osteoclast_differentiation 2 128 0.009417 0.1412
13 hsa04014_Ras_signaling_pathway 2 236 0.02981 0.3832

lncRNA-mediated sponge

(Download full result)

Num lncRNA miRNAs           miRNAs count     Gene Sponge regulatory network lncRNA log2FC lncRNA pvalue Gene log2FC Gene pvalue lncRNA-gene Pearson correlation
1 ZNF667-AS1 hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-18a-3p;hsa-miR-18a-5p;hsa-miR-21-5p;hsa-miR-222-5p;hsa-miR-27a-3p;hsa-miR-484;hsa-miR-627-5p 11 TGFBR3 Sponge network -4.019 0.00137 -4.817 0 0.44
2

MAGI2-AS3

 hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-18a-3p;hsa-miR-18a-5p;hsa-miR-21-5p;hsa-miR-222-5p;hsa-miR-27a-3p;hsa-miR-33a-3p;hsa-miR-590-3p 11 TGFBR3 Sponge network -4.563 0 -4.817 0 0.366
3 NR2F2-AS1 hsa-miR-15a-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-18a-3p;hsa-miR-18a-5p;hsa-miR-222-5p;hsa-miR-27a-3p;hsa-miR-27b-3p;hsa-miR-590-3p;hsa-miR-944 10 TGFBR3 Sponge network -3.785 0.00281 -4.817 0 0.36
4 RP11-166D19.1 hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-18a-3p;hsa-miR-18a-5p;hsa-miR-222-5p;hsa-miR-27a-3p;hsa-miR-33a-3p;hsa-miR-484;hsa-miR-590-3p;hsa-miR-627-5p;hsa-miR-944 13 TGFBR3 Sponge network -4.209 2.0E-5 -4.817 0 0.359
5

MIR143HG

 hsa-miR-141-3p;hsa-miR-15b-3p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-2110;hsa-miR-30c-5p;hsa-miR-30d-3p;hsa-miR-30d-5p;hsa-miR-30e-5p;hsa-miR-330-5p;hsa-miR-616-5p;hsa-miR-92a-3p 12 WNT5A Sponge network -6.51 0 -0.335 0.71496 0.356
6 HAND2-AS1 hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-18a-3p;hsa-miR-18a-5p;hsa-miR-21-5p;hsa-miR-222-5p;hsa-miR-27a-3p;hsa-miR-33a-3p;hsa-miR-590-3p;hsa-miR-944 12 TGFBR3 Sponge network -7.871 0 -4.817 0 0.35
7 NR2F1-AS1 hsa-miR-15a-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-18a-3p;hsa-miR-18a-5p;hsa-miR-21-5p;hsa-miR-222-5p;hsa-miR-27a-3p;hsa-miR-484;hsa-miR-590-3p 10 TGFBR3 Sponge network -2.961 0.00154 -4.817 0 0.336
8

MIR143HG

 hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-18a-3p;hsa-miR-18a-5p;hsa-miR-21-5p;hsa-miR-222-5p;hsa-miR-33a-3p;hsa-miR-484;hsa-miR-590-3p;hsa-miR-627-5p 12 TGFBR3 Sponge network -6.51 0 -4.817 0 0.323
9 EMX2OS hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-18a-3p;hsa-miR-18a-5p;hsa-miR-21-5p;hsa-miR-222-5p;hsa-miR-27a-3p;hsa-miR-484;hsa-miR-590-3p;hsa-miR-627-5p;hsa-miR-944 13 TGFBR3 Sponge network -6.205 0.00015 -4.817 0 0.319
10

MAGI2-AS3

 hsa-miR-141-3p;hsa-miR-15b-3p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-2110;hsa-miR-30c-5p;hsa-miR-30d-3p;hsa-miR-30e-5p;hsa-miR-330-5p;hsa-miR-616-5p;hsa-miR-92a-3p 11 WNT5A Sponge network -4.563 0 -0.335 0.71496 0.31
11 MIR497HG hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-18a-3p;hsa-miR-18a-5p;hsa-miR-21-5p;hsa-miR-222-5p;hsa-miR-27a-3p;hsa-miR-33a-3p 10 TGFBR3 Sponge network -6.146 0.00024 -4.817 0 0.303
12 FAM66C hsa-miR-15a-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-18a-3p;hsa-miR-18a-5p;hsa-miR-21-5p;hsa-miR-222-5p;hsa-miR-27a-3p;hsa-miR-484;hsa-miR-590-3p 10 TGFBR3 Sponge network -2.927 0.00012 -4.817 0 0.292
13 ADAMTS9-AS1 hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-18a-3p;hsa-miR-18a-5p;hsa-miR-21-5p;hsa-miR-222-5p;hsa-miR-27a-3p;hsa-miR-590-3p;hsa-miR-627-5p 11 TGFBR3 Sponge network -8.573 0.00012 -4.817 0 0.279
14 RP11-130L8.1 hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-18a-5p;hsa-miR-21-5p;hsa-miR-222-5p;hsa-miR-27a-3p;hsa-miR-590-3p;hsa-miR-627-5p;hsa-miR-944 10 TGFBR3 Sponge network -4.329 1.0E-5 -4.817 0 0.278
15 DNM3OS hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-18a-3p;hsa-miR-18a-5p;hsa-miR-222-5p;hsa-miR-27a-3p;hsa-miR-33a-3p;hsa-miR-484;hsa-miR-590-3p 11 TGFBR3 Sponge network -3.933 0.00059 -4.817 0 0.267

Quest ID: 285274355a378772c33af2c6d792af75